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 The lipid A biosynthetic pathway is exclusive to gram-negative bacteria, thus 
making it an ideal target for antimicrobial drug discovery. Furthermore, two distinct 
acyltransferases, UDP-GlcNAc acyltransferase (LpxA) and UDP-3-O-(Acyl)-GlcN 
acyltransferase (LpxD), display structural and functional similarities within the pathway. 
Such similarities offer the potential to design inhibitors capable of targeting both active 
sites. This provides a unique paradigm to combating antimicrobial resistance by 
decreasing the likelihood that the bacteria would obtain resistance, through increasing the 
number of mutations necessary for the microbe to survive the therapeutic.  
 Phage display was used to identify several LpxD-inhibitory peptides, one of 
which (RJPXD33) also inhibited LpxA (LpxD Kd = 7 M; LpxA Kd = 22 M) and one 
which was found to be selective for LpxD (RJPXD34; Kd = 31 M). Both peptides 
displayed antimicrobial activity when expressed as N-terminal fusions to thioredoxin. A 
fluorescence polarization (FP) binding assay was developed for LpxD utilizing a 
fluorescein-labeled RJPXD33 (Kd = 600 nM) and for LpxA using a fluorescein-labeled 
Peptide 920 (Kd = 200 nM). With the FP binding assay, RJPXD33 was shown to bind 
competitively with acyl-ACP. RJPXD33 was co-crystallized with LpxA, in order to gain 
an understanding of how RJPXD33 binds to LpxA. The structural data suggested that 
RJPXD33 mimics the acyl-phosphopantetheine moiety of acyl-acyl carrier protein 
(ACP), the native substrate of LpxA. Biochemical characterization of truncated variations 
of RJPXD33 confirmed this model and showed that smaller peptides could be 
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synthesized that could inhibit LpxA with similar potency. While RJPXD33 could not be 
crystallized with LpxD, a crosslinking strategy using photo-affinity derivatives of 
RJPXD33 was developed for mapping the peptide-protein interactions. Finally, the FP 
binding assay was employed to screen a small molecule library (~120,000 compounds) 
against LpxD. The hits were reconfirmed with a continuous, fluorescent enzyme assay 
developed for both LpxA and LpxD. Eleven compounds ranging in potency (IC50’s = 0.1 
– 30 M) were identified, three of which demonstrated in vivo toxicity in Escherichia 
coli lacking the multidrug efflux pump, TolC. These molecules provide a foundation for 





Current Trends in Antimicrobial Chemotherapy. 
 The discovery and clinical utilization of antimicrobial chemotherapeutic agents in 
the late 1930’s was a monumental feat towards combating bacterial pathogenesis world-
wide (1). However, increases in clinical antimicrobial resistance to most of the currently 
used therapeutics has threatened to offset such advances (2). In addition, increases in the 
number of immune-compromised populations owing to advances in organ transplants, 
individuals with acquired immune deficiency disease (AIDs), and advances in treating 
burn victims has seen an emergence of new pathogenic organisms and the reemergence 
of microbial pathogens long thought to be completely curable (3). The constant threat of 
“deliberate emergence” of pathogens released into society through bioterrorism plots, 
further poses a significant threat to public health and welfare. Despite the necessity for 
novel chemotherapeutics to thwart these trends, only two antibacterial drugs with novel 
scaffolds and modes of action have been clinically approved from the late 1960’s to 2008 
(4). It has been hypothesized that lower profit margins, owing to decreased life-span of 
compounds, have effectively lessened pharmaceutical impact on development of 
antimicrobial chemotherapies (5). The aforementioned dilemma has prompted a call for 
the design of novel antibacterial treatments along with development of novel paradigms 
to combat and potentially deplete the unrelenting rise of resistance.  
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One such paradigm includes the design of agents that target virulence factors. The 
overarching hypothesis is that virulence factors are not essential to the growth or survival 
of the pathogen, and thus inhibition of these virulence factors should reduce selective 
pressures on the pathogen, ultimately decreasing the likelihood of resistance. Some 
bacterial toxins have been shown to induce toxicity through effects on mammalian cell 
signaling pathways. The Anthrax lethal factor (LF) has been shown to proteolytically 
cleave kinases within the mitogen activated protein kinase (MAPK) pathway (6). Forino 
et. al. have successfully identified hydroxamate-containing small molecule inhibitors of 
LF which prevented MAPK Kinase (MAPKK) degradation and decreased cytotoxicity to 
murine macrophages in the presence of LF (7). Such molecules offer the potential to 
combat the rapid toxicity associated with this bioterrorism agent, despite the fact that LF 
is not essential to the survival of Anthrax strains. Vibrio cholerae, an infectious pathogen 
which causes diarrhea and water loss, releases cholera toxin (CT) that has been shown to 
ADP-ribosylate regulatory G-proteins preventing the Gs subunit from hydrolyzing GTP, 
leaving the G-protein in a permanent “on state” (8). This state increases intracellular Ca
2+
 
concentration in the intestinal tract, which is followed by a release of H2O and Na
+
 from 
the epithelial lining. Utilizing a whole-cell screen, Hung et. al. were able to target a 
transcriptional regulator of CT (9). Though the molecules did not inhibit growth in 
culture media, they protected mice from colonization of the V. cholerae. This suggested 
that targeting gene expression of toxins is another way to decrease virulence.  
While this paradigm offers much potential, there are disadvantages. One 
disadvantage is that immune-compromised patients lack the ability to clear infections, 
requiring continual dosing regimens or combinatorial therapy with a bactericidal agent. 
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Furthermore, while the small molecules are not directly affecting survival of the 
pathogen, inhibition of virulence factors allows the immune system to eradicate the 
infection. This, by definition, is a selective pressure for survival and growth of the 
pathogen. Further investigation is warranted to conclude that the original hypothesis is 
correct. 
 There has been much focus around the paradigm of designing novel classes of 
antimicrobials which include novel chemical scaffolds and subcellular targets (10). 
Natural products and semi-synthetic derivatives, from underexplored niches, are potential 
examples for finding novel scaffolds with diverse effects. This approach comes with no 
surprise as natural products and their analogues account for ~68% of the antibacterial 
novel chemical entities from 1981 – 2006 (11). One dilemma in screening libraries of 
natural products, especially in whole cell assays, is the risk of re-identification of 
compounds previously identified. This “re-inventing” of the wheel is time consuming and 
offers no new advances in antibacterial drug discovery. Furthermore, producing large 
quantities of natural products can be a daunting task in its own right. Strategies to 
genetically engineer microbes to produce large-scale and novel antimicrobials have been 
an active area of research to address these two problems (12-14). However, to properly 
perform these genetic manipulations a thorough understanding of the biosynthetic 
pathways and the microorganisms are prerequisites, which may require many years of 
basic research. 
More recent approaches towards identifying novel scaffolds have included 
repurposing chemical libraries to screen for antimicrobial inhibitors, as well as 
synthesizing complex combinatorial libraries to expand beyond the chemical space of 
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existing libraries. Miller et. al. identified novel biotin synthase inhibitors from a pre-
existing small molecule library designed to identify protein kinase inhibitors (15). This 
strategy provides a plethora of compounds at the grasp of pharmaceutical companies. 
However, one might question the utilization of compounds targeted towards eukaryotic 
proteins, owing to the potential for adverse side effects. Approaches towards diversifying 
chemical libraries through combinatorial synthetic strategies have been pioneered by 
Stuart Schreiber and colleagues (16). While stereospecific properties of molecules may 
enhance binding, skeletally diverse products may contain a vast number of stereocenters. 
When chemically synthesizing such libraries, one must take into account that the total 
number of isomers of a single molecule synthesized is 2
n
, where n is the number of 
stereocenters. For example, if a single molecule contains 5 stereocenters, and only one 
isomer is active, the library would include 31 unwanted isomers of a single molecule. 
While this disadvantage is time consuming and unproductive, these studies do increase 
our chemical screening space and our fundamental understanding of chemical reactivity, 
and therefore should not be disregarded. 
The strategies mentioned thus far all offer a great contribution towards design and 
identification of novel chemotherapeutic agents against microbial pathogenesis. 
Furthermore, multiple paradigms and strategies should be pursued in order to prevent a 
bottleneck in scientific discovery. A strategy that has not received much attention is the 
design of chemotherapeutics to target multiple proteins on the basis of similar structure 
and functionality. Inhibition of two enzymes decreases the likelihood of target mutation-
mediated resistance by increasing the minimal number of essential gene mutations 
required for the pathogen to obtain resistance to the therapeutic (17). While most efforts 
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have been aimed at the ATPase domains of DNA transcription machinery (gyrase and 
topoisomerase), other classes such as peptidoglycan ligases are beginning to emerge as 
potential targets (18-21). However, this strategy is not without disadvantage, as difficulty 
in targeting two similar proteins could result in unwanted promiscuity which could 
present adverse side effects. Further, identifying targets essential to microbial survival 
that share highly similar structure and function may prove to be considerably difficult. 
We felt the lipid A biosynthetic pathway could be an appropriate molecular avenue for 
this approach owing to the high degree of structural and functional similarity between the 
early acyltransferases in the pathway. Furthermore, lipid A is essential and exclusive to 
gram-negative microbes decreasing the likelihood of adverse interactions with the host 
organism. The results we have obtained suggest this strategy can be utilized effectively in 
antimicrobial drug design. 
Lipid A Biosynthesis: The Hydrophobic Anchor of Lipopolysaccharide. 
 Lipopolysaccharide (LPS) constitutes the outer monolayer of the outer cell 
membrane of gram-negative bacteria (22,23). This protective sheath encapsulates the 
bacterial peptidoglycan wall, as opposed to gram-positive bacteria which contain an 
environmentally exposed peptidoglycan layer (24). LPS has been shown to act as a 
permeability barrier to protect gram negative pathogens from hydrophobic antibiotics 
(25,26). LPS is constructed of three domains (Figure 1.1): a multi-acylated 
oligosaccharide, known as lipid A, which is essential to growth of most gram-negative 
bacteria (27), a core polysaccharide region and O-antigen polysaccharide both of which 
are not essential, but play a role in virulence (22). Lipid A also plays a structural role, 
anchoring LPS to the outer cell membrane. Furthermore, there are many diverse 
6 
 
modifications to lipid A which play a functional role in protection of gram-negative 
bacteria from environmental stresses and the mammalian immune response (22). 
 
Figure 1.1. The inner and outer membranes of gram-negative bacteria.  
 Lipid A initiates the host-cell immune response by stimulating the release of 
Tumor Necrosis Factor (TNF) and IL- through activation of the Toll-Like Receptor 4 
(TLR-4) and a co-receptor MD-2 (28-31). Though necessary for the host immune 
response to clear bacterial infections, over-stimulation of these responses can lead to 
septic shock and ultimately death (32). The biological significance of lipid A in relation 
to the host-immune response further makes lipid A biosynthesis an attractive target for 
discovery and design of antimicrobial therapeutics.  
 Lipid A biosynthesis is comprised of nine constitutive steps as shown in Figure 
1.2. The pathway begins with the catalytic acylation of UDP-N-acetylglucosamine (UDP-
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GlcNAc) via LpxA which utilizes an acyl-acyl carrier protein (ACP) donor (33,34). The 
formation of UDP-3-O-(R-3-hydroxymyristoyl)-N-acetylglucosamine in Escherichia coli 
has been shown to be a thermodynamically unfavorable reaction with a Keq = 0.01 (35). 
The deacylation of the N-acetyl moiety, catalyzed by LpxC, has been shown to be the 
first irreversible step in lipid A biosynthesis and a key regulatory step of the pathway in 
E. coli (36-38). A subsequent acylation of the free amine by the acyltransferase LpxD, 
constitutes the third reaction step in the pathway (39). UDP is catalytically hydrolyzed to 
UMP and a diacyl-glucosamine-1-phosphate moiety (lipid X) by LpxH (40,41). Lipid X 
is subsequently linked to the product of LpxD via LpxB to form a disaccharide with a 
1,6--linkage (42). The lipid A kinase, LpxK, phosphorylates the 4’-OH of the -linked 
tetra acylated disaccharide (43). KdtA, also known as WaaA, adds two Kdo moieties onto 
the 6’-hydroxyl, which is followed by the addition of two acyl-chains by two separate 
membrane bound acyltransferases, LpxL and LpxM (44-48). With the exception of the 
first three soluble cytosolic enzymes (LpxA, LpxC and LpxD), the latter steps are all 
catalyzed on the cytosolic face of the inner membrane. The mature Kdo2-lipid A species 
is subsequently flipped to the periplasmic face of the inner membrane by an ATP-
dependent transporter, MsbA (49). The translocation of LPS to the outer membrane is 
carried out by a trans-envelope complex stretching from the inner membrane to the outer 
membrane by a series of lipopolysaccharide transport proteins (LptA–G) (50). However, 





Figure 1.2. Representative scheme of lipid A biosynthesis in E. coli. Acyltransferases are highlighted in 
red. 
 The core of lipid A tends to be relatively conserved through the glucosamine 
moiety, though there are organisms such as Leptospira interrogans which catalytically 
convert the 3-hydroxyl of UDP-GlcNAc to an amine (51,52). Beyond the glucosamine 
backbone, one of the more highly variable moieties is the length of the acyl chains (53-
56). Differences in acyl chains play an important role in recognition by the host-immune 
system (ref 8 and those within). Further variations come about by modifications of 
mature lipid A such as hydrolysis of an acyloxyacyl chain, dephosphorylation of the 1’- 
or 4’-phosphates, and masking of negative charges on the phosphates that different 
organisms use to evade the host immune system (22,57-61). It has been postulated that 
modified lipid A molecules could be utilized for potential vaccination, though discovery 
9 
 
of therapeutics that target the early steps of the pathway may provide for a more direct 
route in preventing bacterial sepsis (8). 
 Temperature sensitive mutants of early steps of lipid A biosynthesis have 
demonstrated that lipid A is required for viability of the microbe (36,39,62). However, 
the essentiality of a gene target is not always indicative of a good drug target.  The 
discovery of E. coli LpxC inhibitors provided validation that the committed step of lipid 
A biosynthesis was a viable drug target (63). This initial discovery of the first LpxC 
inhibitor led to a concerted effort towards optimizing the compound in order to find broad 
spectrum LpxC inhibitors (63-67). More recently Benson et. al. have demonstrated that 
overexpression of an inhibitory peptide targeting LpxA displayed toxicity in E. coli (68), 
thus chemically validating LpxA as a antimicrobial target.  
 LpxA is a trimeric enzyme and the first discovered to contain the unique left-
handed -helical (LH) fold (69,70). The active site of LpxA has been shown to be 
comprised of a catalytic histidine (His125 in E. coli) which deprotonates the 3-OH of the 
UDP-GlcNAc moiety allowing for nucleophilic attack into the thioester of the acyl-ACP 
substrate (71). Wyckoff and Raetz also demonstrated that all three active sites of the 
trimer are active. LpxA from several species have been co-crystallized with substrates 
UDP-GlcNAc and acyl-methylphosphopantethenine as well as products UDP-3-O-(R-3-
hydroxyacyl)-GlcNAc (51,72,73). The acyl chains of both ligands were shown to bind in 
the hydrophobic pocket between two monomeric subunits of the LpxA trimer, 
highlighting the acyl chain binding region of LpxA. The -helical C-terminal region of 
LpxA was further implicated in binding of the UDP moiety of both substrate and product, 
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and thus termed the UDP binding domain. The binding modalities of these ligands will be 
further discussed in chapter 4. 
 Though LpxA has been extensively studied, only more recently the second 
acyltransferase, LpxD has begun finding attention in literature. LpxD displays high 
sequence homology to LpxA (27.2% from a Clustal Pairwise Analysis). Hunter and 
coworkers were able to crystallize LpxD from C. trachomatis (74). Interestingly, it was 
not previously known that LpxD could bind UDP-GlcNAc, but Hunter and coworkers 
effectively demonstrated crystallographic evidence of the ligand•protein interaction, 
albeit at concentrations above physiological conditions. LpxD is comprised of an -
helical UDP binding domain, a LH motif highly similar to that of LpxA (Figure 1.3), 
and a C-terminal -helical extension region. Structural differences arise at the C-terminus 
of the LH domain between C. trachomatis LpxD and E. coli LpxD, which account for 
the differences in acyl chain selectivity of the two proteins (75). The profound similarity 
between the structure and function of LpxA and LpxD, combined with the knowledge 
that they could bind similar ligands, led us to the hypothesis that LpxD and LpxA could 
potentially be exploited to discover dual-targeting inhibitory probes for the future design 




Figure 1.3. Structures of E. coli LpxA (left; PDB 1LXA) and E. coli LpxD (right; PDB 3EH0) (70,75). 
Phage Display as a Tool for Probe Design. 
 Filamentous phage, such as M13, have the ability to display foreign, small 
peptides on their coat surface (76). Two of the M13 coat proteins are the major coat 
protein (pVIII) and a minor coat protein (pIII). Both of these have demonstrated the 
ability to display foreign peptides at the ends of their sequences (77).  The pIII coat is 
more widely utilized today as there are only five copies expressed on the cellular surface 
compared to the pVIII protein which contains nearly 2700 copies per phage particle (77-
80). This provides for lower valency and ultimately higher binding affinity of identified 
ligands. M13 phage are lysogenic and thus are not plaque forming, requiring a method for 
selection and detection. This was overcome by equipping the M13 with a lacZ15 -
complementation factor which permits for blue-white selection in lacZ15 E. coli strains 
that are commercially available (New England BioLabs). 
 Phage display has been a potent tool in the design and discovery of novel peptide 
ligands that disrupt protein-protein interactions (77,81). Peptide probes are widely 
applicable due to the synthetic ease incurred by advances in solid-phase synthesis 
methodology first pioneered by R. Bruce Merrifield (82). The fundamental premise of 
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phage display is the genetic manipulation of bacteriophage to display a random array of 
peptide ligands on their coat protein (Figure 1.4). Panning, or screening, the library 
against an immobilized target can then be used identify bound phage. Phage particles that 
remain unbound can be washed away, where bound phage can be eluted by various 
techniques such as a high acid wash or competitive ligand elution strategies to disrupt 
peptide•target interactions (81,83). Following elution of the bound phage, one can titer 
the eluent to determine the plaque forming units (pfu) and subsequently amplify the 
phage pool by infecting an E. coli culture. Generally three to four rounds are undertaken 
before individual phage are tittered and the individual “plaque” or colony is selected for 
DNA isolation and sequence identification. From the DNA sequence identification, the 
peptide sequence can be determined. This strategy offers unique advantages from the 
standpoint that little knowledge of the target is necessary to perform the screen. One is 
only limited by the ability to purify and immobilized the target of interest, as 
commercially available libraries of phage expressing random peptides are widely 
available.  
Phage display experiments identified the LpxA-binding peptide, peptide 920 
(P920), which was then used to demonstrate that overexpression of phage display-
selected peptides could function as chemical knockout tools of essential microbial 
enzymes (68). Later, LpxA inhibition studies suggested that the peptide was a 
competitive inhibitor of acyl-ACP, providing the molecular basis for its antimicrobial 
activity (84). However, crystallization studies of the LpxA•P920 and LpxA•UDP-
GlcNAc complexes demonstrated that P920 overlaps with portions of the fatty acid 




Figure 1.4. General schematic of the phage display screening process. 
Thesis Outline and Significance. 
 Acyltransferases within the lipid A pathway are attractive targets for antimicrobial 
chemotherapy. However, hurdles such as lack of non-radioactive enzyme assays and 
difficulties in obtaining large quantities of substrates have prevented chemical genomics 
approaches towards identifying inhibitory small molecules. This thesis work 
encompasses the development of novel chemical and biological tools to address these 
challenges for studying the early acyltransferases of lipid A biosynthesis.  
 One of the first issues addressed was the development of a non-radioactive 
enzyme assay for both LpxA and LpxD (85). Acyl-ACP is a valuable substrate and 
necessary for the chemoenzymatic production of UDP-3-O-(R-3-hydroxyacyl)-GlcN, the 
LpxD substrate. Currently employed methods for generating acyl-ACP are arduous and 
require large amounts of E. coli due to toxicity associated with the overexpression of apo-
ACP (86-89). This challenge is addressed in chapter 2 with an overexpression and 
purification system for E. coli holo-ACP. The production of holo-ACP combined with the 
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utilization of a soluble acyl-ACP synthetase recently characterized by Cronan and 
coworkers allowed for large production of acyl-ACP (90,91). Once the substrates were 
obtained, a continuous fluorescent enzyme assay was developed by exploiting the lone 
thiol unveiled on ACP during LpxA and LpxD catalysis. The reaction can be monitored 
by labeling the free thiol with a thiol-specific labeling reagent, ThioGlo1 for continuous 
monitoring of product turnover. 
 The development of a continuous enzyme assay marked a platform for testing 
inhibitory probes identified from a phage display screen against LpxD (92). As 
hypothesized, dual targeting peptides were discovered along with a more selective LpxD 
inhibitory peptide. Chapter 3 discusses the discovery of these peptides and the 
development of a fluorescence polarization (FP) assay for high-throughput screening 
(HTS) efforts. The development of the FP assay was essential to minimize the need for 
large quantities of substrates to perform an HTS assay. We further elaborated on the 
potential of P920 and utilized this as a tool for probing LpxA. Furthermore, this FP assay 
was used to demonstrate that the peptides were binding to LpxD and/or LpxA exclusive 
of R-3-hydroxymyristoyl-ACP highlighting a potential basis for the dual inhibitory 
functionality. 
 The discovery of the dual targeting inhibitor, RJPXD33 laid the foundation for a 
multi-faceted approach to identify small molecule acyltransferase inhibitors capable of 
penetrating the cellular membrane of gram-negative bacteria (Figure 1.5). One approach 
would be the rational design and synthesis of RJPXD33 peptidomimetics with enhanced 
bioavailability, decreased susceptibility to proteolysis, and the ability to maintain 
secondary structure necessary for inhibition. However, in order to identify 
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peptidomimetics it is essential to understand the fundamental mechanism of how the 
inhibitor binds to the target protein. To address this issue a structural and biochemical 
study was undertaken to provide molecular insights into RJPXD33 mechanism of binding 
(chapter 4). A second approach, discussed in chapter 5, was the use of an FP binding 
assay to screen a large library of small molecular weight compounds (~120,000) against 
LpxD. These experiments led to the identification of several small molecule LpxD 
inhibitors, some with antimicrobial activity against E. coli.  
 
Figure 1.5. Use of peptides to probe lipid A biosynthesis. Phage display led directly to the discovery of the 
dual targeting inhibitor RJPXD33. This allowed for an in vivo overexpression assay, a lead peptide which 
can be further developed into peptidomimetics, and a surrogate ligand used in a high-throughput binding 
assay to identify small molecule inhibitors. 
 
 This thesis work has provided a novel toolset for future investigations into the 
early acyltransferases of lipid A biosynthesis. Furthermore, it establishes the proof-of-
principle that dual targeting inhibitory molecules can be identified against LpxA and 
LpxD. The probes and techniques established herein should provide a lasting impact on 






1. Cohen, M. L. (1992) Science 257, 1050-1055 
2. Neu, H. C. (1992) Science 257, 1064-1073 
3. Boucher, H. W., Talbot, G. H., Bradley, J. S., Edwards, J. E., Gilbert, D., Rice, L. 
B., Scheld, M., Spellberg, B., and Bartlett, J. (2009) Clinical Infectious Diseases 
48, 1-12 
4. Clatworthy, A. E., Pierson, E., and Hung, D. T. (2007) Nat Chem Biol 3, 541-548 
5. Nathan, C., and Goldberg, F. M. (2005) Nature Reviews Drug Discovery 4, 887-
891 
6. Duesbery, N. S., Webb, C. P., Leppla, S. H., Gordon, V. M., Klimpel, K. R., 
Copeland, T. D., Ahn, N. G., Oskarsson, M. K., Fukasawa, K., Paull, K. D., and 
Vande Woude, G. F. (1998) Science 280, 734-737 
7. Forino, M., Johnson, S., Wong, T. Y., Rozanov, D. V., Savinov, A. Y., Li, W., 
Fattorusso, R., Becattini, B., Orry, A. J., Jung, D., Abagyan, R. A., Smith, J. W., 
Alibek, K., Liddington, R. C., Strongin, A. Y., and Pellecchia, M. (2005) Proc. 
Natl. Acad. Sci. U. S. A. 102, 9499-9504 
8. Cassel, D., and Pfeuffer, T. (1978) Proc. Natl. Acad. Sci. U. S. A. 75, 2669-2673 
9. Hung, D. T., Shakhnovich, E. A., Pierson, E., and Mekalanos, J. J. (2005) Science 
310, 670-674 
10. Fischbach, M. A., and Walsh, C. T. (2009) Science 325, 1089-1093 
11. Newman, D. J., and Cragg, G. M. (2007) Journal of Natural Products 70, 461-
477 
12. Ajikumar, P. K., Xiao, W.-H., Tyo, K. E. J., Wang, Y., Simeon, F., Leonard, E., 
Mucha, O., Phon, T. H., Pfeifer, B., and Stephanopoulos, G. (2010) Science 330, 
70-74 
13. Pfeifer, B. A., Admiraal, S. J., Gramajo, H., Cane, D. E., and Khosla, C. (2001) 
Science 291, 1790-1792 
14. McDaniel, R., Thamchaipenet, A., Gustafsson, C., Fu, H., Betlach, M., and 
Ashley, G. (1999) Proc. Natl. Acad. Sci. U. S. A. 96, 1846-1851 
15. Miller, J. R., Dunham, S., Mochalkin, I., Banotai, C., Bowman, M., Buist, S., 
Dunkle, B., Hanna, D., Harwood, H. J., Huband, M. D., Karnovsky, A., Kuhn, 
M., Limberakis, C., Liu, J. Y., Mehrens, S., Mueller, W. T., Narasimhan, L., 
Ogden, A., Ohren, J., Prasad, J. V. N. V., Shelly, J. A., Skerlos, L., Sulavik, M., 
Thomas, V. H., VanderRoest, S., Wang, L., Wang, Z., Whitton, A., Zhu, T., and 
Stover, C. K. (2009) Proc. Natl. Acad. Sci. U. S. A. 106, 1737-1742 
16. Schreiber, S. L. (2000) Science 287, 1964-1969 
17. Charifson, P. S., Grillot, A.-L., Grossman, T. H., Parsons, J. D., Badia, M., 
Bellon, S., Deininger, D. D., Drumm, J. E., Gross, C. H., LeTiran, A., Liao, Y., 
Mani, N., Nicolau, D. P., Perola, E., Ronkin, S., Shannon, D., Swenson, L. L., 
Tang, Q., Tessier, P. R., Tian, S.-K., Trudeau, M., Wang, T., Wei, Y., Zhang, H., 
and Stamos, D. (2008) Journal of Medicinal Chemistry 51, 5243-5263 
18. Cheng, J., Thanassi, J. A., Thoma, C. L., Bradbury, B. J., Deshpande, M., and 
Pucci, M. J. (2007) Antimicrob. Agents Chemother. 51, 2445-2453 
17 
 
19. Grossman, T. H., Bartels, D. J., Mullin, S., Gross, C. H., Parsons, J. D., Liao, Y., 
Grillot, A.-L., Stamos, D., Olson, E. R., Charifson, P. S., and Mani, N. (2007) 
Antimicrob. Agents Chemother. 51, 657-666 
20. Hossion, A. M. L., Zamami, Y., Kandahary, R. K., Tsuchiya, T., Ogawa, W., 
Iwado, A., and Sasaki, K. (2011) Journal of Medicinal Chemistry 54, 3686-3703 
21. Tomasic, T., Sink, R., Zidar, N., Fic, A., Contreras-Martel, C., Dessen, A., Patin, 
D., Blanot, D., Mueller-Premru, M., Gobec, S., Zega, A., Kikelj, D., and Masic, 
L. P. (2012) Acs Medicinal Chemistry Letters 3, 626-630 
22. Raetz, C. R. H., Reynolds, C. M., Trent, M. S., and Bishop, R. E. (2007) Annu. 
Rev. Biochem. 76, 295-329 
23. Raetz, C. R. H., and Whitfield, C. (2002) Annu. Rev. Biochem. 71, 635-700 
24. Barreteau, H., Kovac, A., Boniface, A., Sova, M., Gobec, S., and Blanot, D. 
(2008) Fems Microbiol. Rev. 32, 168-207 
25. Vaara, M. (1993) Antimicrob. Agents Chemother. 37, 354-356 
26. Vuorio, R., and Vaara, M. (1992) Antimicrob. Agents Chemother. 36, 826-829 
27. Meredith, T. C., Aggarwal, P., Mamal, U., Lindner, B., and Woodard, R. W. 
(2006) ACS Chem. Biol. 1, 33-42 
28. Beutler, B., and Cerami, A. (1988) Annu. Rev. Biochem. 57, 505-518 
29. Poltorak, A., He, X., Smirnova, I., Liu, M.-Y., Huffel, C. V., Du, X., Birdwell, D., 
Alejos, E., Silva, M., Galanos, C., Freudenberg, M., Ricciardi-Castagnoli, P., 
Layton, B., and Beutler, B. (1998) Science 282, 2085-2088 
30. Hoshino, K., Takeuchi, O., Kawai, T., Sanjo, H., Ogawa, T., Takeda, Y., Takeda, 
K., and Akira, S. (1999) The Journal of Immunology 162, 3749-3752 
31. Visintin, A., Halmen, K. A., Latz, E., Monks, B. G., and Golenbock, D. T. (2005) 
The Journal of Immunology 175, 6465-6472 
32. Russell, J. A. (2006) New England Journal of Medicine 355, 1699-1713 
33. Anderson, M. S., Bulawa, C. E., and Raetz, C. R. (1985) J. Biol. Chem. 260, 
15536-15541 
34. Anderson, M. S., Robertson, A. D., Macher, I., and Raetz, C. R. H. (1988) 
Biochemistry 27, 1908-1917 
35. Anderson, M. S., Bull, H. G., Galloway, S. M., Kelly, T. M., Mohan, S., Radika, 
K., and Raetz, C. R. H. (1993) J. Biol. Chem. 268, 19858-19865 
36. Young, K., Silver, L. L., Bramhill, D., Cameron, P., Eveland, S. S., Raetz, C. R. 
H., Hyland, S. A., and Anderson, M. S. (1995) J. Biol. Chem. 270, 30384-30391 
37. Jackman, J. E., Raetz, C. R. H., and Fierke, C. A. (1999) Biochemistry 38, 1902-
1911 
38. Ogura, T., Inoue, K., Tatsuta, T., Suzaki, T., Karata, K., Young, K., Su, L.-H., 
Fierke, C. A., Jackman, J. E., Raetz, C. R. H., Coleman, J., Tomoyasu, T., and 
Matsuzawa, H. (1999) Molecular Microbiology 31, 833-844 
39. Kelly, T. M., Stachula, S. A., Raetz, C. R. H., and Anderson, M. S. (1993) J. Biol. 
Chem. 268, 19866-19874 
40. Babinski, K. J., Kanjilal, S. J., and Raetz, C. R. H. (2002) J. Biol. Chem. 277, 
25947-25956 
41. Babinski, K. J., Ribeiro, A. A., and Raetz, C. R. H. (2002) J. Biol. Chem. 277, 
25937-25946 
42. Metzger, L. E., and Raetz, C. R. H. (2009) Biochemistry 48, 11559-11571 
18 
 
43. Garrett, T. A., Que, N. L. S., and Raetz, C. R. H. (1998) J. Biol. Chem. 273, 
12457-12465 
44. Reynolds, C. M., and Raetz, C. R. H. (2009) Biochemistry 48, 9627-9640 
45. Carty, S. M., Sreekumar, K. R., and Raetz, C. R. H. (1999) J. Biol. Chem. 274, 
9677-9685 
46. Vorachek-Warren, M. K., Ramirez, S., Cotter, R. J., and Raetz, C. R. H. (2002) J. 
Biol. Chem. 277, 14194-14205 
47. Heinrichs, D. E., Monteiro, M. A., Perry, M. B., and Whitfield, C. (1998) J. Biol. 
Chem. 273, 8849-8859 
48. Isobe, T., White, K. A., Allen, A. G., Peacock, M., Raetz, C. R. H., and Maskell, 
D. J. (1999) J. Bacteriol. 181, 2648-2651 
49. Zhou, Z., White, K. A., Polissi, A., Georgopoulos, C., and Raetz, C. R. H. (1998) 
J. Biol. Chem. 273, 12466-12475 
50. Freinkman, E., Okuda, S., Ruiz, N., and Kahne, D. (2012) Biochemistry 51, 4800-
4806 
51. Robins, L. I., Williams, A. H., and Raetz, C. R. H. (2009) Biochemistry 48, 6191-
6201 
52. Sweet, C. R., Williams, A. H., Karbarz, M. J., Werts, C., Kalb, S. R., Cotter, R. J., 
and Raetz, C. R. H. (2004) J. Biol. Chem. 279, 25411-25419 
53. Dotson, G. D., Kaltashov, I. A., Cotter, R. J., and Raetz, C. R. H. (1998) J. 
Bacteriol. 180, 330-337 
54. Odegaard, T. J., Kaltashov, I. A., Cotter, R. J., Steeghs, L., vanderLey, P., Khan, 
S., Maskell, D. J., and Raetz, C. R. H. (1997) J. Biol. Chem. 272, 19688-19696 
55. Wyckoff, T. J. O., Lin, S. H., Cotter, R. J., Dotson, G. D., and Raetz, C. R. H. 
(1998) J. Biol. Chem. 273, 32369-32372 
56. Sweet, C. R., Lin, S., Cotter, R. J., and Raetz, C. R. H. (2001) J. Biol. Chem. 276, 
19565-19574 
57. Kanistanon, D., Hajjar, A. M., Pelletier, M. R., Gallagher, L. A., Kalhorn, T., 
Shaffer, S. A., Goodlett, D. R., Rohmer, L., Brittnacher, M. J., Skerrett, S. J., and 
Ernst, R. K. (2008) PLoS Pathog. 4 
58. Kawasaki, K., Ernst, R. K., and Miller, S. I. (2004) J. Biol. Chem. 279, 20044-
20048 
59. Reynolds, C. M., Ribeiro, A. A., McGrath, S. C., Cotter, R. J., Raetz, C. R. H., 
and Trent, M. S. (2006) J. Biol. Chem. 281, 21974-21987 
60. Zhou, Z. M., Lin, S. H., Cotter, R. J., and Raetz, C. R. H. (1999) J. Biol. Chem. 
274, 18503-18514 
61. Zhou, Z. M., Ribeiro, A. A., Lin, S. H., Cotter, R. J., Miller, S. I., and Raetz, C. R. 
H. (2001) J. Biol. Chem. 276, 43111-43121 
62. Galloway, S. M., and Raetz, C. R. H. (1990) J. Biol. Chem. 265, 6394-6402 
63. Onishi, H. R., Pelak, B. A., Gerckens, L. S., Silver, L. L., Kahan, F. M., Chen, M. 
H., Patchett, A. A., Galloway, S. M., Hyland, S. A., Anderson, M. S., and Raetz, 
C. R. H. (1996) Science 274, 980-982 
64. Barb, A. W., Jiang, L., Raetz, C. R. H., and Zhou, P. (2007) Proc. Natl. Acad. Sci. 
U. S. A. 104, 18433-18438 
65. Barb, A. W., Leavy, T. M., Robins, L. I., Guan, Z. Q., Six, D. A., Zhou, P., 
Bertozzi, C. R., and Raetz, C. R. H. (2009) Biochemistry 48, 3068-3077 
19 
 
66. Jackman, J. E., Fierke, C. A., Tumey, L. N., Pirrung, M., Uchiyama, T., Tahir, S. 
H., Hindsgaul, O., and Raetz, C. R. H. (2000) J. Biol. Chem. 275, 11002-11009 
67. McClerren, A., Endsley, S., Bowman, J., Andersen, N., Guan, Z., and Rudolph, J. 
(2005) Biochemistry 44, 16574-16583 
68. Benson, R. E., Gottlin, E. B., Christensen, D. J., and Hamilton, P. T. (2003) 
Antimicrob. Agents Chemother. 47, 2875-2881 
69. Pfitzner, U., Raetz, C. R. H., and Roderick, S. L. (1995) Proteins 22, 191-192 
70. Raetz, C. R. H., and Roderick, S. L. (1995) Science 270, 997-1000 
71. Wyckoff, T. J. O., and Raetz, C. R. H. (1999) J. Biol. Chem. 274, 27047-27055 
72. Ulaganathan, V., Buetow, L., and Hunter, W. N. (2007) Journal of Molecular 
Biology 369, 305-312 
73. Williams, A. H., and Raetz, C. R. H. (2007) Proc. Natl. Acad. Sci. U. S. A. 104, 
13543-13550 
74. Buetow, L., Smith, T. K., Dawson, A., Fyffe, S., and Hunter, W. N. (2007) Proc. 
Natl. Acad. Sci. U. S. A. 104, 4321-4326 
75. Bartling, C. M., and Raetz, C. R. H. (2009) Biochemistry 48, 8672-8683 
76. Smith, G. P. (1985) Science 228, 1315-1317 
77. Smith, G. P., and Petrenko, V. A. (1997) Chemical Reviews 97, 391-410 
78. Cwirla, S. E., Peters, E. A., Barrett, R. W., and Dower, W. J. (1990) Proc. Natl. 
Acad. Sci. U. S. A. 87, 6378-6382 
79. Scott, J. K., and Smith, G. P. (1990) Science 249, 386-390 
80. Devlin, J. J., Panganiban, L. C., and Devlin, P. E. (1990) Science 249, 404-406 
81. Sparks, A. B., Adey, N. B., Cwirla, S., and Kay, B. K. (1996) Phage display of 
peptides and proteins: A laboratory manual, 227-253 
82. Merrifield, R. B. (1963) J. Am. Chem. Soc. 85, 2149-& 
83. Oldenburg, K. R., Loganathan, D., Goldstein, I. J., Schultz, P. G., and Gallop, M. 
A. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 5393-5397 
84. Williams, A. H., Immormino, R. M., Gewirth, D. T., and Raetz, C. R. H. (2006) 
Proc. Natl. Acad. Sci. U. S. A. 103, 10877-10882 
85. Jenkins, R. J., and Dotson, G. D. (2012) Analytical Biochemistry 425, 21-27 
86. Keating, D. H., Carey, M. R., and Cronan, J. E. (1995) J. Biol. Chem. 270, 22229-
22235 
87. Rock, C. O., and Cronan, J. E., Jr. (1979) J. Biol. Chem. 254, 7116-7122 
88. Rock, C. O., and Cronan, J. E., Jr. (1979) J. Biol. Chem. 254, 9778-9785 
89. Byers, D. M., and Gong, H. S. (2007) Biochemistry and Cell Biology-Biochimie 
Et Biologie Cellulaire 85, 649-662 
90. Jiang, Y. F., Chan, C. H., and Cronan, J. E. (2006) Biochemistry 45, 10008-10019 
91. Jiang, Y. F., Morgan-Kiss, R. M., Campbell, J. W., Chan, C. H., and Cronan, J. E. 
(2010) Biochemistry 49, 718-726 










The enzymes in early lipid A biosynthesis are highly conserved in Gram-negative 
pathogens and represent potential targets for antibacterial development. Both biochemical 
and genetic studies have demonstrated the essential nature of LpxA and LpxD 
acyltransferases in Gram-negative organisms (1-3). For the most part, current assays 
utilized for assaying enzymes within the lipid A biosynthetic pathway use radiolabeled 
substrates coupled with thin layer chromatography and phosphorimaging development. 
These assays have endured over the years due to their reliability and the inherent need for 
sensitivity as a result of scarcity and solubility of substrates. Fluorescence-based 
enzymatic assays have proven to be highly sensitive and robust, and unlike radioactivity-
based assays, have been used widely for high throughput screening (HTS) (4). The 
continuous fluorescent assays established herein are initial efforts to facilitate the 
identification and evaluation of LpxA/D inhibitors to be used as research probes and/or 
antimicrobial leads. 
The thermodynamically unfavorable reaction catalyzed by LpxA presented one of 
the main difficulties in developing an assay (5). In order to circumvent this problem, it 
was envisioned that labeling of one of the products would allow the reaction to proceed 
1
The work described in this chapter has been published. Jenkins, RJ and Dotson, GD. “A continuous 




continuously in the forward direction. The lone thiol unveiled upon ACP directly 
following acyl transfer to the core glucosamine ring offered the greatest feasibility to 
perform such a reaction. As an added benefit, this assay would also be amenable for use 
with the reaction catalyzed by LpxD (6,7).  
In order to develop this assay, the thiol specific labeling reagent, ThioGlo1, was 
utilized to continuously monitor the generation of free ACP over the course of the LpxA 
or LpxD reactions (Figure 2.1). ThioGlo1 contains a coumarin ring covalently linked to a  
fluorescence quenching maleimide (8). Upon thiol addition into the maleimide, the 
coumarin ring fluoresces at ex = 379 nm and em = 513 nm, allowing the generation of 
holo-ACP to be monitored in real time. These assays marked the first non-radioactive 
assay for either acyltransferase and allowed for rapid and sensitive analysis of catalytic 
turnover for both LpxA and LpxD. 
 
Figure 2.1. Methodology for monitoring catalysis of LpxA and LpxD. Early enzymatic steps of LPS 
biosynthesis in E. coli (top). Formation of the ThioGlo-ACP conjugate formed from holo-ACP produced in 






Materials and Methods 
Materials. R-3-hydroxymyristic acid was purchased from Wako Chemicals. 
Tris(2-carboxyethyl)phosphine hydrochloride (TCEP), isopropanol, magnesium chloride 
and buffer reagents were purchased from Thermo Fisher Scientific. L-arabinose, ATP, 
and UDP-N-acetylglucosamine were purchased from Sigma-Aldrich. Benzonase, 
ThioGlo
®
1, and E. coli Rosetta(DE3)/pLysS cells were purchased from EMD Chemicals 
(Novagen). E. coli XL-1 Blue cells were purchased from Strategene. Isopropyl β-D-1-
thiogalactopyranoside (IPTG), E. coli BL21-AI cells were purchased from Invitrogen. 
Bio-Gel P2 was purchased from Bio-Rad. All DNA modifying and restriction enzymes 
were purchased from New England Biolabs. 
Cloning of E. coli lpxA, lpxC, lpxD, acpP, acpS and Vibrio harveyi aasS. PCR 
protocols were carried out under standard conditions utilizing Pfu DNA polymerase and 
DNA obtained from the E. coli K-12 strain MG1655 or the V. harveyi ATCC14126 
strain. To perform the amplifications of the individual genes the following primers were 
used: lpxA (forward 5'-
GCGCCATATGATTGATAAATCCGCCTTTGTGCATCCAACCGC, reverse 5'-
CGCGCTCGAGTTAACGAATCAGACCGCGCGTTGAGCG); lpxC (forward 5'-
GCGCCATATGATGATCAAACAAAGGACACT , reverse 5'-
GCGCCTCGAGTGCCAGTACAGCTGAAGGCG); lpxD (forward 5'-
CATCACCATCACCATCACGCTCAATTCGACTGGCTGATTTAGCG , reverse 5'-
CGCGCTCGAGTTAGTCTTGTTGATTAACCTTGCGCTC); acpP (forward 5'-
GCGCCATATGAGCACTATCGAAGAACGCGTTAAGAAAATTATC, reverse 5'-




GCGCCTCGAGACTTTCAATAATTACCGTGGCACAAGC); V. harveyi aasS 
(forward 5'-GCGCCATATGAACCAGTATGTAAAT, reverse 5'-
GCGCCTCGAGCAGATGAAGTTTACGCAG).  
The PCR products for both lpxA, and acpP were cloned into pET24a using NdeI 
and XhoI restriction sites (underlined). The XhoI-restricted PCR product for lpxD was 
cloned into pET23d which had been NcoI restricted, T4 DNA polymerase filled-in, and 
then restricted with XhoI. Each of the PCR products for lpxC, acpS and aasS were cloned 
into pET23a using NdeI and XhoI restriction sites. All plasmids were transformed into E. 
coli XL-1 Blue cells for amplification and plasmids isolated from these cell lines were 
sequenced at the University of Michigan Sequencing Core Facility. From these confirmed 
plasmids the following E. coli expression strains were constructed: BL21-
AI/pET24a::lpxA, Rosetta (DE3)/pLysS/pET23a::lpxC-his6, Rosetta 
(DE3)/pLysS/pET23d::his6-lpxD, BL21-AI/pET24a::acpP/pET23a::acpS-his6, BL21-
AI/pET23a::aasS-his6.  Genes containing a 6 histidine tag coding region are indicated by 
his6 in the above construct names.  The his6 in front of the gene name denotes a 5’ 
histidine coding region, whereas the his6 after the gene name denotes a 3’ histidine 
coding region. 
Cell cultures. Strains of interest were used to inoculate 500 mL LB (Lennox) or 
TB media containing the appropriate antibiotic(s), and incubated while shaking (250 rpm) 
at 37 °C until an OD600 of 0.6-1.0 was reached.  The cultures were then induced with 
either 1 mM IPTG (Rosetta DE3/pLysS strains) or 0.2% L-arabinose/1 mM IPTG (BL21-
AI strains). Unless otherwise noted, cells were induced at 37 °C and allowed to incubate 
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at 37 °C for 4 hours post-induction. Cells were harvested by centrifugation at 5,000 x g 
for 10 min at 4 °C, suspended in 10 mL of buffer and stored at -80 °C. Cell suspensions 
were thawed and disrupted by French press at 20,000 psi. Cellular debris was removed by 
centrifugation at 20,000 x g for 30 min at 4 °C and the resultant crude cytosol used for 
protein purification. 
Purification of LpxA. For LpxA purification, 10 mL of crude cytosol in 20 mM 
potassium phosphate (KPhos) buffer, 20% glycerol pH 7.0 was applied to a 10 mL 
Reactive Green 19 column, which had been pre-equilibrated in the same buffer.  The 
column was washed successively with 50 mL of loading buffer containing 0 M, 0.5 M, 
and 1 M NaCl.  LpxA eluted with the 1 M NaCl fractions and was dialyzed overnight at 4 
°C against 4 L of 20 mM Tris-HCl, 10% glycerol pH 8.0. The enzyme was then loaded 
onto an 8 mL Source 15Q column, washed with 24 ml of loading buffer and eluted with a 
gradient from 0-500 mM NaCl. LpxA was desalted on a Bio-Gel P2 column equilibrated 
in 20 mM HEPES pH 8.0. The purified LpxA was analyzed by SDS-PAGE and its 





molecular weight of LpxA was confirmed by MALDI-TOF Mass spectrometry (MS) at 
the University of Michigan Protein Structure Facility. 
Purification of LpxC-His6 and His6-LpxD. For His6-LpxD purification, Benzonase 
(Novagen) was added after cell lysis and the lysate was incubated for 30 min on ice prior 
to centrifugation at 20,000 x g. Ten milliliters of crude cytosol in 20 mM HEPES, 50 mM 
imidazole pH 8.0 was loaded onto 3 mL of Ni-NTA resin (Qiagen) equilibrated in the 
same buffer.  The resin was washed with 10 column volumes of loading buffer containing 
500 mM NaCl and then eluted with 20 mM HEPES, 250 mM imidazole pH 8.0.  Purified 
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His6-LpxD and LpxC-His6 were desalted on a Bio-Gel P2 column and analyzed by SDS-









 for LpxD).  
Purification of holo-ACP. A slightly modified protocol from Broadwater and Fox 
was utilized to prepare holo-ACP (9). Holo-ACP was produced in cells expressing both 
apo-ACP (acpP gene product) and holo-ACP synthetase (acpS gene product). Protein 
was expressed as describe above (Cell culture) except cells were cooled to 18 °C prior to 
induction and then allowed to grow overnight at 18 °C. To the cellular lysate, in 20 mM 
HEPES, 1 mM TCEP pH 8.0 (20 mL), 20 mL of cold isopropanol was added slowly and 
while gently mixing for 1 hour at 4 °C. The resulting suspension was centrifuged at 
20,000 x g for 30 min at 4 °C. The supernatant was removed and to this 40 mL of 20 mM 
HEPES, 1 mM TCEP pH 8.0 was added. This solution was loaded onto a Source 15Q 
column (8 mL). A gradient of 20 mM HEPES, 1 mM TCEP, pH 8.0 containing 0 - 500 
mM NaCl was performed and holo-ACP eluted at approximately 300 mM NaCl as 
judged by SDS-PAGE analysis. The protein was subsequently desalted on a P2 Bio-Gel 
column in 20 mM HEPES, 1 mM TCEP, pH 8.0. The protein was freeze dried and stored 
at -20 °C. Protein concentrations were measured via BioRad protein assay. The molecular 
weight of holo-ACP was confirmed by MALDI-TOF Mass spectrometry (MS) at the 
University of Michigan Protein Structure Facility.  
Purification of V. harveyi AasS-His6. Expression and purification of the soluble 
acyl-ACP synthetase (AasS) was carried out under the same conditions as His6-LpxD and 
LpxC-His6. Following elution from the Ni-NTA resin, AasS was desalted on a Bio-Gel 
P2 column in 20 mM Tris-HCl pH 7.5, 10% glycerol, 1 mM EDTA, 0.1 mM TCEP and 
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0.002% Triton-X100 as previously described for optimal storage (10). The desalted 
protein was aliquoted into microcentrifuge tubes and stored at -80 °C. Protein 





Acylation of holo-ACP. Acylation was carried out as previously described with 
slight modifications (10). Holo-ACP was reduced for 1 hour at room temperature in the 
presence of two equivalence of TCEP prior to the loading of the fatty acid. The acylation 
reaction contained, in a final volume of 10 ml, 40 M reduced holo-ACP, 5 mM ATP, 5 
mM MgCl2, 100 M TCEP, 0.01% Triton X-100, 100 g of AasS, and 150 M R-3-
hydroxymyristic acid in 100 mM Tris, pH 7.5. The reaction was incubated at 30 °C for 45 
min and another 50 g of AasS was added. After 20 min of additional incubation at 30 
°C, the reaction was cooled and loaded directly onto a Source 15Q column (8 mL) 
equilibrated in 20 mM HEPES pH 8.0. The column was washed with 3 column volumes 
of equilibration buffer and eluted with an 80 mL linear gradient of 0 - 500 mM NaCl. 
Acyl-ACP eluted at approximately 300 mM NaCl and was subsequently desalted via a 
Bio-Gel P2 column and lyophilized. 
Synthesis and purification of ThioGlo-ACP conjugate. 1 mL of holo-ACP (100 
M) was incubated with 1 mM TCEP and 132 M of ThioGlo for 25 min (5% DMSO 
final concentration). Following the 25 min, an additional 132 M of ThioGlo was added 
and mixed by pipetting up and down multiple times. The solution was incubated for an 
additional 35 min. The mixture was desalted on a Bio-Rad P2 size-exclusion column 
equilibrated in 20 mM HEPES pH 8. Protein concentrations were determined using Bio-
Rad Protein assay with R-3-hydroxymyristoyl-ACP as a standard. 
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Synthesis of UDP-3-O-(R-3-hydroxmyristoyl)-GlcN. 50 M holo-ACP was 
reduced for 1 hour at room temperature with 3 mM TCEP in 100 mM Tris-HCl pH 7.6 
containing 0.01% Triton-X100. Following reduction of ACP, 3 mM ATP, 3 mM MgCl2, 
150 M R-3-hydroxymyristic acid, and 150 g of AasS were added to the centrifuge tube 
at a final volume of 5 mL and the tube was incubated at 37 °C for 15 min. Substrate 
synthesis was initiated by the addition of LpxA, LpxC and UDP-GlcNAc at 
concentrations of 30 g/mL, 50 g/mL and 500 M and the solution was incubated for 
45 min at 37 °C. Following the 45 min incubation, 100 M of R-3-hydroxmyristic acid, 
30 g/mL LpxA, 30 g/mL AasS, and 50 g/mL LpxC were added and incubated for an 
additional 30 min. The solution was added to a round bottom flask containing silica gel 
(20 mg) and the water removed by rotary evaporation. The dried silica gel was added to a 
silica column (2 g) pre-equilibrated in 75:25 hexanes/ethyl acetate (EtOAc). The silica 
was washed with 100 mL 75:25 hexanes/EtOAc to remove the R-3-hydroxmyristic acid. 
The plug was subsequently washed with 50 mL of 25:15:4:2 v/v/v/v dichloromethane 
(DCM)/methanol (MeOH)/water/acetic acid. The solvent was evaporated off and the 
resulting solid was resuspended in 1 mL of DMSO and filtered through a .2 micron filter 
to remove any silica gel. UDP-3-O-(R-3-hydroxmyristoyl)-GlcN was purified by HPLC 
using 0.05% ammonium acetate and acetonitrile on a reverse phase C18 semi-prep 
column as reported by Anderson and Raetz (11). Purified UDP-3-O-(R-3-
hydroxymyristoyl)-GlcN was lyophilized, dissolved in water and frozen at -80 °C until 





) (6). The purified product was subjected to analytical HPLC and negative ion 
electrospray ionization mass spectrometry (ESI-MS) for characterization.  
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Fluorescent enzyme assay for LpxA and LpxD. Assays were performed at 25 °C in 
Corning black, 96-well half-area plates and all solutions were made up in 20 mM HEPES 
pH 8.0 with a final assay volume of 100 L. A SpectraMax M5 (Molecular Devices) 
plate reader was used to monitor fluorescence, with PMT sensitivity set at low to prevent 
saturation and number of readings set to 100. First, 50 L of 20 M ThioGlo solution 
was added to 20 L of various concentrations of 3-hydroxymyristoly-ACP and 20 L of 
various concentrations of UDP-GlcNAc or UDP-3-O-(R-3-hydroxymyristolyl)-GlcN. 
This mixture was incubated in the dark at 25 °C for 5 min to allow any unacylated ACP 
to react with the ThioGlo solution. To initiate the reaction, 10 L of 100 nM 
acyltransferase solution was added directly to the well, mixed gently and the plate was 
read continuously at ex = 379 nm and em = 513 nm for 10 min at 15 s intervals. It 
should be noted that 100 nM LpxA or LpxD solutions were made fresh between each run 
from 1 mg/mL stock solution of purified enzymes. All reactions were performed in 
triplicate. 
Data Analysis. Initial velocities were calculated through linear regression analysis 
during the first 2 min of the assay. Km's were determined by non-linear regression 
analysis using KaleidaGraph software, from plots of initial velocities versus substrate 
concentrations, while holding the other substrate at saturating conditions (eq. 1). Control 
reactions lacking individual substrate or enzyme components were performed to 
demonstrate that increase in fluorescence was both enzyme and substrate dependent, and 
that no individual substrate or enzyme was causing an increase in relative fluorescence 
over time. Linear dependence of enzyme concentration with respect to initial velocity 
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was established through altering enzyme concentration while holding both substrates 
constant. 
 




3H-benzo[f]chromene-2-carboxylate) has been used in the fluorescent detection of free 
thiol containing compounds in analytical HPLC, biological tissue samples, cell free 
extracts, and HTS (4,12-14). This reagent has been used to determine protein thiol 
concentrations as low as 10 nM (15).  Therefore, we sought to utilize this reagent to 
monitor holo-ACP generation during LpxA and LpxD catalysis. With this assay the rate 
of holo-ACP production can be monitored continuously by detection of the fluorescent 
ThioGlo-ACP conjugate (ex = 379 nm and em = 513 nm).  A standard fluorescent curve 
was generated by reading the fluorescence of various concentrations (0.1-16 M; 100 
L) of ThioGlo-ACP conjugate in a Corning black, 96-well half-area plate (Figure 2.2).  
No deviation from linearity was noted upon adding ThioGlo at concentrations up to 10 
M.  Under these conditions 1 M ThioGlo-ACP gives 99.8 RFU.  
 
𝑣 =
𝑉𝑚𝑎𝑥  𝑆 






Figure 2.2. Fluorescence vs. [ThioGlo-ACP] plot.  The fluorescence of various concentrations of purified 
ThioGlo-ACP conjugate, in 20 mM HEPES pH 8 (total volume 100 L), was determined at 25 °C using a 
SpectraMax M5 plate reader. 
 
Optimization of the reagents utilized for the kinetic analysis needed to be 
performed prior to kinetic characterization of LpxA. Final concentrations of LpxA were 
found to be optimal at 10 nM, where linear velocities could be measured within the first 2 
min of a 10 min assay. It should be noted that when LpxA was diluted in assay buffer 
alone to 100 nM stock solution, the enzyme lost activity over time while on ice. 
Therefore, enzyme from a 1 mg/mL stock was diluted fresh to 100 nM for each assay and 
used immediately.  
Since the free thiol generated upon holo-ACP generation is prone to oxidation and 
disulfide formation, which would interfere with ThioGlo conjugation, initially TCEP (a 
reducing agent) was employed to mitigate this possibility. However, TCEP proved to 
interfere with the reproducibility of labeling holo-ACP with ThioGlo in agreement with 
previous protein labeling studies with maleimide reagents in the presence of TCEP (16). 
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Exclusion of reducing agent resulted in greatly enhanced reproducibility and robustness 
of the assay, and thiol oxidation over the course of the assay time was not an issue.   
Once conditions were optimized, time dependent-turnover of LpxA catalyzed acyl 
group transfer was demonstrated (Figure 2.3). Control reactions where individual 
components were omitted showed no increase in fluorescence, demonstrating that the 
generation of holo-ACP was being measured. The assay shows a linear dependence on 
enzyme concentration up to 20 nM which further establishes that the kinetics of LpxA are 
being measured, rather than the kinetics of ThioGlo conjugation to ACP (Figure 2.4).  
The specific activity for LpxA under our reaction conditions (25 °C) is 7.7 mol/min/mg 
(kcat = 3.6 s
-1
).  This value is reasonably lower (36 %) than literature values where assays 
were performed at a higher temperature (30 °C) (17). 
 
Figure 2.3. Reaction progress curves of the complete LpxA reaction (○), and control reactions without 
either nucleotide (□), acyl-ACP (◊), or acyltransferase (x).  The complete LpxA assay mixture contained 20 
mM HEPES (pH 8), 40 M R-3-hydroxymyristoyl-ACP, 4 mM UDP-GlcNAc, 10 M ThioGlo, and 10 nM 
LpxA (added 5 minutes after ThioGlo) in a final volume of 100 L.  The reaction was incubated at 25 °C 
and its progress was monitored continuously at ex = 379 nm and em = 513 nm for 10 min at 15 s intervals.  





Figure 2.4. Linear dependence of initial reaction velocity with varying LpxA concentrations using the 
ThioGlo coupled fluorescence assay.  The assays were run as described under Figure 3 caption, with 
varying amounts of LpxA being added.  The assay showed a  linear relationship between activity and 
enzyme concentration up to 20 nM LpxA. 
 
The steady state kinetic parameters of LpxA were analyzed to determine the 
utility of the assay. The Michaelis-Menten constant for UDP-GlcNAc was established by 
holding acyl-ACP constant at 40 M and varying UDP-GlcNAc between concentrations 
of 150 M – 4.0 mM (Figure 2.5A). The Km was found to be 600 ± 80 M, which was in 
good accordance with the previously published values of 100-800 M (17,18). Next the 
Km for acyl-ACP was established by holding UDP-GlcNAc constant at 4.0 mM 
concentration, while varying acyl-ACP between 1-40 M and plotting the initial velocity 
versus acyl-ACP concentration (Figure 2.5B). The Km of acyl-ACP was determined to be 
10 ± 1 M.  Estimates of acyl-ACP Km using the radioactivity assay ranged from 1.5-5 
M (17,19). However, LpxA has an unfavorable equilibrium constant in the forward 
direction (Keq = 0.01), and this has made it difficult to precisely measure the conversion 
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of radiolabeled UDP-GlcNAc to acylated product under high nucleotide and low acyl-
ACP concentrations (18). With our current assay ThioGlo is able to sequester the holo-
ACP product, thus mitigating the unfavorable Keq and allowing accurate determination of 
the Km of acyl-ACP. 
 
Figure 2.5. Saturation kinetics of LpxA for (A; left) UDP-GlcNAc and (B; right) R-3-hydroxymyristoyl-
ACP.  A) UDP-GlcNAc was varied between 150-4000 M, while holding acyl-ACP constant at 40 M. B) 
R-3-hydroxymyristoyl-ACP was varied over a concentration range of 1-40 M, while holding UDP-
GlcNAc constant at 4000 M. Assays were run in triplicate. 
 
In order to assay LpxD, the nucleotide substrate, UDP-3-O-(R-3-
hydroxymyristoyl)-GlcN, needed to be synthesized. The current method for obtaining 
LpxD substrate is through an LpxA and LpxC coupled enzymatic process, utilizing acyl-
ACP and UDP-GlcNAc as substrates (2,6). To decrease the amount of acyl-ACP 
necessary for this coupled assay, the soluble V. harveyi acyl-ACP synthetase was utilized 
to produce and continuously regenerate R-3-hydroxymyristoyl-ACP in situ from holo-




Figure 2.6. Schematic representation of UDP-3-O-(R-3-hydroxymyristoyl)-GlcN enzymatic preparation. 
The LpxA catalyzed formation of UDP-3-O-(R-3-hydroxyacyl)-GlcNAc is coupled directly to LpxC to 
form UDP-3-O-(R-3-hydroxymyristoyl)-GlcN, while AasS catalyzes the acylation of holo-ACP to 
regenerate acyl-ACP. 
 
Upon obtaining UDP-3-O-(R-3-hydroxymristoyl)-GlcN, the kinetic parameters of 
His6-LpxD were next established. It should be noted that previous literature precedent has 
established there is no difference in activity between His6-LpxD and native LpxD (6). 
Acyl-ACP was varied between 2.5-40 M while holding UDP-3-O-(R-3-
hydroxymyristoyl)-GlcN at 19 M to determine the Km of acyl-ACP (Figure 2.7A). The 
Km was 12 ± 2 M which is higher than the previously published literature value of 3 M 
(6). This discrepancy could be attributed to various reasons such as cysteine labeling of 
free thiols on LpxD which may interfere with acyl-ACP binding, differences in substrate 
quantitation between the two studies or a combination of the two.  To determine the Km 
of UDP-3-O-(R-3-hydroxymyristoyl)-GlcN, the substrate was varied between 0.35-19 
M, while holding acyl-ACP constant at 40 M (Figure 2.7B). Again the Km established, 
4 ± 0.5 M, correlated well to the reported value of 2.5 M. The LpxD specific activity 
calculated from the Vmax and protein concentration used in the steady state analysis was 
determined to be 5.0 mol/min/mg (kcat = 3.0 s
-1
). Previously determined specific activity 
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for LpxD was 8.9mol/min/mg (30 °C) (6).  These results demonstrated the 
reproducibility and robustness for the ThioGlo assay for LpxD. 
 
Figure 2.7. Saturation kinetics of LpxD for (A; left) R-3-hydroxymyristoyl-ACP and (B; right) UDP-3-O-
(R-3-hydroxymyristoyl)-GlcN.  A) acyl-ACP was varied over a concentration range of 1-40 M while 
holding UDP-3-O-(R-3-hydroxymyristoyl)-GlcN constant at 19 M.  B) UDP-3-O-(R-3-
hydroxymyristoyl)-GlcN was varied over a range of 0.35-19 M while holding acyl-ACP constant at 40 
M. Assays were run in triplicate. 
 
 We have developed the first non-radioactive kinetic assay for both LpxA and 
LpxD. The above results demonstrate the utility of the thiol-specific reagent ThioGlo for 
use in kinetic assays involving turnover of acyl-ACP to holo-ACP. We have established 
and optimized the conditions essential to monitor turnover, and with these optimized 
conditions have determined the Michaelis-Mentin constants for both E. coli LpxA and 
LpxD substrates. These values are in good agreement with previously reported literature 
values. The assay is fast, continuous, and can be adapted to 384-well plates for high-
throughput screening, depending on the readiness of non-commercially available 
substrates (acyl-ACP and UDP-3-O-(R-3-hydroxymyristoyl)-GlcN). This assay will be 
instrumental in the discovery and characterization of small-molecule inhibitors of LpxA 
and LpxD. Beyond LPS biosynthesis, holo-ACP is involved in a multitude of 
36 
 
biochemical pathways such as membrane phospholipid biosynthesis (20), fatty acid 
biosynthesis (21), polyketide biosynthesis (22), and quorum sensing (23), to name but a 
few. Therefore, this assay may find broad utility across various research communities. 
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LpxA and LpxD acyltransferases have been touted as novel subcellular targets for 
antimicrobial development (1,2), and while in vivo chemical inhibition of the lpxA gene 
product has been shown to display antimicrobial activity (2), there are no known in vivo 
active LpxD inhibitors.  Of the two acyltransferases, LpxD is thought to be the better 
target due to the build-up of UDP-3-O-(R-3-hydroxyacyl) glucosamine that occurs in 
LpxD mutants grown at non-permissive temperatures (1,3). This compound has 
detergent-like properties and its accumulation is potentially toxic.  
Peptides that bind to and inhibit essential enzymes have been invaluable as 
chemical probes used to validate intracellular targets, modulate biosynthetic pathways, 
develop target-specific binding assays, as well as serve as templates for the development 
of more pharmacologically relevant peptidomimetic agents (4-6). Therefore, as a prelude 
to small molecule inhibitor discovery, here we describe the use of a random phage-bound 
peptide library, combined with ligand-competitive phage elution, to identify bioactive 
LpxD inhibitory peptides. One bioactive peptide in particular was identified that binds to 
and inhibits both purified recombinant LpxD and LpxA. A single peptide with the ability 
to inhibit two steps in early lipid A biosynthesis represents a unique finding and serves as 
a new example of a dual targeting antimicrobial agent. 
1
The work described in this chapter has been published. Jenkins, RJ and Dotson, GD. “Dual targeting 
antibacterial peptide of early lipid A biosynthesis.” ACS Chemical Biology 7 (2012), 1170-1177. 
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Materials and Methods 
Materials. All DNA primers and Dynabeads M-270 Streptavidin were purchased 
from Invitrogen. Ph.D.-12 phage peptide library, pTYB2, pTYB3, Chitin beads, and all 
restriction enzymes were purchased from New England BioLabs (NEB). Plasmid 
pBirAcm was purchased from Avidity. Bio-Rad Protein Assay and Bio-Gel P2 size-
exclusion resin were purchased from Bio-Rad. LB (Lennox) Broth and Agar, and 
dextrose were purchased from Difco. Peptide synthesis reagents and resins were 
purchased from Anaspec. Fluorescein isothiocyanate (FITC) was purchased from Acros 
Organics. ThioGlo1 reagent was purchased from Calbiochem. R-3-hydroxymyristic acid 
was obtained from Wako Chemicals. All antibiotics and other chemicals were purchased 
in the highest grade from Fisher Scientific or Sigma-Aldrich. SpectraMax M5 
spectrophotometer was from Molecular Devices. DNA sequencing was performed at the 
University of Michigan DNA Sequencing Core. 
Cell culture. A list of all bacteria strains and plasmids are described in Table 3.1.  
All LB-containing agar plates were incubated at 37 °C unless otherwise indicated. For 
protein expression and purification, all recombinant E. coli/T7 RNA polymerase 
promoter constructs were grown in 1 L baffled flask containing 250 mL of LB media 
supplemented with the appropriate antibiotics. The flasks were shaken (250 rpm) at 37 °C 
until the cells reached an optical density of OD600 = 0.6. To the cultures were added either 
1 mM isopropyl -D-1-thiogalactopyranoside (IPTG) (Rosetta (DE3)) or 1 mM IPTG and 
0.2% L-arabinose (BL21-AI), and the cultures allowed to incubate at 37 °C for an 
additional 4 hours. Cells were harvested at 4 °C by centrifugation at 6,000 x g, and lysed 
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by French press.  Crude cytosol was prepared by centrifugation of the lysate at 20,000 x g 
for 30 min at 4 °C. 
Biotinylation of E. coli LpxD. The lpxD gene was amplified (pfu DNA 
polymerase) from E. coli MG1655 (ATCC) genomic DNA by standard PCR protocols 
with two primers corresponding to the 5’ and 3’ ends of the lpxD open reading frame. 
The forward primer was CCTTCAATTCGACTGGCTGATTTAGCG and the reverse 
primer was ATATCTCGAGGTCTTGTTGATTAACCTTGCGCTCAAGCG. The 
forward primer begins at the second codon of the lpxD reading frame, while the reverse 
primer contains an XhoI restriction site (underlined) in place of the lpxD stop codon. The 
purified PCR product was restricted with XhoI and inserted into pTYB3, which had 
undergone digestion with NcoI, a fill-in reaction with T4 DNA polymerase, and 
restriction with XhoI.  The resulting construct, pUMGD13, contained lpxD with a 3’-
intein coding tag. 
In a second lpxD-intein construct, a coding region for a 15-amino acid biotin 
ligase-recognition motif was inserted in frame with, and upstream of, the intein tag 
coding region in pTYB2 (5,7,8). The following complimentary primer pair, 5'-
GGGCTGAACGATATTTTTGAAGCGCAGAAAATTGAATGGCATGAACCG-3' and 
5'-CGGTTCATGCCATTCAATTTTCTGCGCTTCAAAAATATCGTTCAGCCC-3', 
coding for the biotin ligase-recognition motif (underlined), was blunt-end cloned into the 
SmaI restriction site of pTYB2 to give pTYB2btc.  The XbaI/XhoI restriction fragment 
from pUMGD13, containing the lpxD open reading frame, was ligated into XbaI/XhoI 
restricted pTYB2btc to give pUMRJ4 and the insert was confirmed by DNA sequencing.  
41 
 
The resulting pUMRJ4 construct contained lpxD with a 3’-biotin ligase recognition motif 
coding region followed by the intein coding region. 
 E. coli BL21-AI harboring the plasmids pUMRJ4 and pBirAcm was grown in a 
250 mL culture, as indicated above, with D-biotin (12 mg/L) added along with IPTG and 
L-arabinose during induction. Crude cytosol (10 mL) was applied to a 5 mL Chitin bead 
column, and the column wash with 10 column volumes of 20 mM Tris-HCl pH 8.0. 
Immobilized LpxD was cleaved from the intein fusion tag by washing the column with 
15 mL of 50 mM mercaptoethane sulfonic acid (MESNA), stopping the flow, and 
allowing the resin to sit overnight at 4 °C. Fresh buffer was then added to the top of the 
column and biotinylated LpxD eluted in the first 4 mL. The protein was desalted through 
a 12 mL Bio-Gel P2 column in 20 mM Tris-HCl pH 8.0. The purified biotinylated LpxD 
was analyzed by SDS-PAGE and its concentration determined by UV absorbance at 280 




). Molar ratio of biotin was determined by 4'-
hydroxyazobenzene-2-carboxylic acid (HABA) assay per manufacturer’s protocol 
(Thermo Scientific). 
Phage Display. Streptavidin-conjugated Dynabeads (10 L) were washed three 
times with 100 L of 50 mM Tris-HCl, pH 7.5, 150 mM NaCl (TBS). Biotinylated LpxD 
(4 pmol) in 100 L of TBS was added to Dynabeads (10 L) and the mixture was 
allowed to incubate at room temperature for 30 min. The beads were magnetically 
separated from the supernatant and washed five times with 100 L TBS. To the affinity 
captured biotinylated LpxD, 100 M biotin (100 L) was added and incubated at room 
temperature for 10 min to block any excess streptavidin sites. The beads were again 
washed five times with 100 L TBS. Phage-bound peptide library (Ph.D.-12), at a 
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concentration of 1 x 10
9
 – 1 x 10
10
 plaque forming units (pfu), was added to the 
immobilized LpxD in a total volume of 100 L TBS. This suspension was allowed to 
incubate for 45 min at room temperature with gentle mixing. Following the incubation 
period the supernatant was removed and the beads were washed ten times with 100 L 
TBS. Bound phage were eluted by incubating for 15 min with gentle mixing with either 
50 M acyl carrier protein (ACP) or 500 M UDP-GlcNAc in 100 L TBS buffer. The 
phage were then amplified by direct infection with E. coli XL1 Blue, isolated and tittered 
as previously described, and used in the next cycle (9). In subsequent rounds of panning 
0.1% Tween 20 was added to all TBS buffer containing solutions. Following rounds three 
and four, individual plaques were selected at random, phage purified, and the DNA from 
each was sequenced. 
Bioactivity Assay. pACYC184, isolated from E. coli JM110 (dam
-
), was restricted 
with HindIII/BclI and the fragment containing the p15A origin of replication and 
chloramphenicol resistance marker was isolated from a 1% agarose gel. The araC and 
thioredoxin genes were individually amplified using pBAD-thio as the template in two 
separate PCR reactions. For the araC gene 5'-
GCGCTGATCATTATGACAACTTGACGGCTACATCATTC-3' was used as the 
forward primer and 5'-GCGCCATATGTATGTATATCTCCTTCTTAAAGTTAAAC-3' 
was used as the reverse primer. The forward primer contains a BclI restriction site 
(underlined) and the reverse primer contains an NdeI restriction site (underlined). The 
thioredoxin gene was cloned using 5'-
GCGCCATATGGGGCCCGGATCTGATAAAATTATTCATCTGACTG-3' as the 
forward primer (NdeI site underlined) and 5'-CCGAGGAGAGGGTTAGGGATAGGC-3' 
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as the reverse primer. The araC PCR product was restricted with BclI and NdeI, while the 
thioredoxin containing PCR fragment was restricted with NdeI and HindIII. These two 
inserts were ligated together with the BclI/HindIII restricted pACYC184 fragment, 
resulting in the formation of pUMRJ100. 
Complementary DNA oligonucleotides coding for peptides identified from phage 
display were purchased in the following format, NdeI-(dodecapeptide coding region)-
ApaI.  Complementary oligos were mixed in equal molar ratios, heated to 94 °C for 2 
min, and allowed to cool to room temperature over several minutes.  The hybridized 
oligos were restricted with NdeI and ApaI, pooled, and ligated into pUMRJ100 restricted 
with the same enzymes.  The ligation mixture was used to transform competent E. coli 
XL1 Blue and the transformed cells selected on LB agar containing 1% dextrose and 10 
g/mL chloramphenicol (LB-cam/dex) at 37 °C overnight.  Seventy-two random colonies 
were selected and streaked onto both LB-cam/dex and LB-cam/0.2% L-arabinose (8 
replica plates).  Colonies which grew on the dextrose containing plates, but not on the 
arabinose containing plates were indicative of bioactive peptide expression.  Plasmids 
were isolated from colonies on the LB-cam/dex plates having the desired phenotype and 
the peptide coding regions determined by DNA sequencing. Empty plasmid vector was 
used as a negative control and showed no toxicity. 
E. coli LpxA and LpxD expression constructs. E. coli His6-LpxD and LpxA were 
expressed and purified as previously described (10). The pUC18::lpxD construct was 
made from a previously described wild-type pET expression construct (10). The lpxD 
gene was excised from the pET construct by XhoI restriction/T4 DNA polymerase fill-in, 
followed by XbaI restriction.  The insert was then ligated into pUC18 which had been 
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restricted with HindIII, filled-in with T4 DNA polymerase, and restricted with XbaI.  The 
resulting lpxD pUC18 construct was designated pUMRJ45. All constructs were verified 
by DNA sequencing. 
Synthesis of Acytransferase substrates. R-3-hydroxymyristoyl-ACP and UDP-3-
O-(R-3-hydroxymyristoyl)-glucosamine were synthesized and purified as previously 
described in chapter 2 (10). 
Fluorescence polarization protein binding assay. Peptides FITC-RJPXD33 
(FITC-(A)TNLYMLPKWDIP-NH2), RJPXD33 (TNLYMLPKWDIP-NH2), RJPXD31 
(QHFMVPDINDMQ-NH2), RJPXD34 (SENNFMLPLLPL-NH2),  and FITC-P920 
(FITC-(A)SSGWMLDPIAGKWSR-NH2) were synthesized using rink-amide resin (0.4 
mmol/g capacity) by established peptide coupling procedures. Labeled peptides contained 
an N-terminal -alanine (A) linker coupled to fluorescein using fluorescein 
isothiocyanate (FITC). Peptides were purified via RP-HPLC and analyzed by 
electrospray ionization mass spectrometry (ESI-MS) at the University of Michigan 
Chemistry Mass Spectrometry Services. Purified peptides were suspended in DMSO and 
diluted to a concentration of 200 nM in 20 mM HEPES, pH 8.0 (~0.1% DMSO). LpxA 
and His6-LpxD were serially diluted to appropriate concentrations in 20 mM HEPES, pH 
8.0 and 45 L of the dilutions were added to 354-well black Costar plates. To this, 5 L 
of labeled peptide was added for a final concentration of 20 nM FITC-peptide. The wells 
were gently mixed and incubated at 30 °C for 15 min. Polarization was measured on a 
SpectraMax M5 plate reader in triplicate with readings taken at ex = 485 nm and em = 
525 nm.  The data for FITC-RJPXD33 binding to LpxD was normalized to the 
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experimentally determined polarization of the fully bound peptide (mPb), and the 
resulting binding curves fit to Hill equation (1) using KaleidaGraph software.   
 
Where  is the fraction of FITC-peptide bound, h is the Hill coefficient, [P] is the 
concentration of protein, and Kd is the dissociation constant of protein•peptide complex.  
For RJPXD33 binding to LpxA the polarization values of the fully bound labeled peptide 
(mPb) and Kd were determined by nonlinear fit of the polarization versus 
[Acyltransferase] plots to Eq. (2).  Where mP is the experimentally determined 
polarization, mPf is the polarization of free FITC-RJPXD33, P is the total amount of 
acyltransferase, and Kd is the dissociation constant of the protein•peptide complex. The 
calculated mPb was then used to normalize the experimental data and the resulting 
binding curves fit to Eq. (1). 
 
 
For competition binding assays, 220-660 nM of acyltransferase was incubated in 
the presence of varying concentrations of unlabeled peptides or acyl-ACP for 10 min at 
30 °C. FITC-labeled peptide (20 nM) was added and incubated in the dark at 30 °C for 15 
min before reading. The [I]50 was determined from the competition binding curve and the 
dissociation constant of the unlabeled ligand was calculated as previously described using 



















Where [I]50 is the free unlabeled ligand (inhibitor) concentration at 50% inhibition, [L]50 
is the free ligand (fluorescent tracer) concentration at 50% inhibition, and [P]0 is the free 
protein concentration at 0% inhibition, Kd is the dissociation constant of the ligand 
(fluorescent tracer), and Ki is the calculated dissociation constant for the unlabeled 
ligand. 
Acyltransferase inhibition assays. The acyltransferase reaction was observed in 
the forward direction using a continuous fluorescent assay. The fluorescent assay detects 
holo-ACP liberation via conjugation with ThioGlo1 reagent, which could be monitored as 
an increase in fluorescence from excitation and emission wavelengths set to ex = 379 nm 
and em = 513 nm. Assays were performed on a SpectraMax M5 microplate reader (auto 
cutoff set to  = 495 nm, PMT set to low and precision set to 40 scans per well) using 
Corning black, 96-well half-area plates. The assay mixture in a final volume of 100 L 
contained 20 mM HEPES pH 7.5, 10 M ThioGlo, 600 M UDP-GlcNAc (LpxA assay) 
or 4.5 M UDP-3-O-(R-3-hyrdoxymyristoyl)-GlcN (LpxD assay), 9 M R-3-
hydroxymyristoyl-ACP, 10 nM acyltransferase and varying concentrations of peptide 
(200 M – 1 M). Assays contained a final concentration of 2% (v/v) DMSO from 
peptide stock solutions. All components with the exception of enzyme were mixed and 
incubated in the dark at 30°C for 5 min. To initiate the reaction, a fresh dilution of 
acyltransferase was added and the reaction was monitored for 10 min. Assays were run in 















and a positive control containing no acyltransferase were used for 100% and 0% relative 
activity, respectively. 
Multicopy suppression. Competent E. coli XL1 Blue/pUMRJ45 were transformed 
separately with pUMRJ40 (pUMRJ100::rjpxd34), pUMRJ41 (pUMRJ100::rjpxd33), or 
pUMRJ100 (control). The transformed cells were grown overnight at 37 °C on LB agar 
containing 1% dextrose, 100 g/mL ampicillin, and 10 g/mL chloramphenicol (LB-
amp/cam/dex).  Single colonies were selected and streaked onto both LB-amp/cam/dex 
and LB-amp/cam/0.2% L-arabinose plates.  These plates were incubated overnight at 37 
°C. 
Results and Discussion 
Table 3.1.  Plasmids and bacterial strains used in this study 
  
Bacterial strain 
or plasmid   
  
Relevant characteristics       Source 
Plasmids 
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Phage display was employed to identify LpxD-binding peptides. LpxD contains a 
C-terminal helical extension spanning 45 Å from the active site contained within its LH 
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core structure that proved to be an ideal position to place a biotin tag for biopanning 
experiments (12,13). Initial attempts at labeling the C-terminus via cleavage of an LpxD-
intein fusion, expressed from pUMGD13, using cysteine-biotin or ethylenediamino-biotin 
failed to generate biotinylated protein (14). As well, other nucleophiles known to cleave 
intein protein fusions, such as mercaptoethane sulfonic acid (MESNA) and/or DTT, also 
failed to cleave the LpxD-intein fusion protein. Therefore, a biotin ligase recognition 
(BLR) motif coding region was cloned upstream of the intein coding region in pTYB2 to 
allow for in vivo biotinylation of protein fusions (7,8).  The construct pUMRJ4 contains 
lpxD cloned upstream of the BLR coding region and upon induction in E. coli BL21-
AI/pBirAcm/pUMRJ4, allows for the expression of a 96 kDa protein fusion (LpxD-BLR 
motif-intein-chitin binding domain). The 96 kDa biotinylated-LpxD intein fusion was 
bound to chitin resin and the intein linkage cleaved using MESNA, resulting in elution of 
biotinylated LpxD (38 kDa). The purified protein contained 0.97 moles of biotin per mole 
of LpxD.  
Phage display screening was performed using the Ph.D.-12 random peptide 
library (NEB), which contains approximately 1.9 billion phage-bound, random 12-amino 
acid peptides fused to the N-terminus of the M13 phage pIII coat protein. Biopanning 
experiments were carried out against biotinylated LpxD immobilized on magnetic beads 
coated with streptavidin (Dynabeads M-270). Bound phage were eluted from 
immobilized LpxD with either UDP-GlcNAc, previously shown to bind to Chlamydia 
trachmoatis LpxD (13), or ACP as competitive ligands.  Peptide coding sequences from 
ten randomly selected phage were obtained after rounds three and four of panning. The 
twenty DNA sequences isolated encoded 17 unique peptides. Peptide sequences were 
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aligned in Clustal W (15) to determine sequence homology (Figure 3.1). A consensus 
YMLP motif was heavily conserved (Figure 3.2, panel a) and identified among a third of 
the sequences, which is similar to the WMLDP motif located within the LpxA-specific 
peptide, peptide 920 (P920; SSGWMLDPIAGKWSR) (5). The aromatic-Met-
hydrophobic motif is heavily conserved among 50% of the sequences, with variations 
between tyrosine and phenylalanine in the lead position. Also, the sequences 
TNLYMLPKWDIP (RJPXD33) and AWWEFNPFAWPY were identified multiple times 
among the twenty isolated phages. 
 
 
Figure 3.1. Multiple sequence alignment of dodecapeptides identified from competition phage display 
experiments. Twenty sequences were aligned using Clustal W (15). Peptides highlighted in bold showed 
antibacterial activity upon expression in E. coli XL1 Blue. Amino acids highlighted in bold reveal a 
consensus motif (Y/FMLP) identified within many of the peptides. RJPXD33 was identified among three 
of the twenty randomly selected colonies, representing 15% of total colonies selected. 
 
The M13 pIII coat protein containing the N-terminal peptide is expressed in the E. 
coli host with a signal sequence immediately upstream of the peptide library site. This 
signal sequence targets the modified pIII protein to the E. coli periplasm wherein the 
signal peptide is cleaved (16).  While this compartmentalization away from the cytoplasm 
is ideal for amplifying and expressing phage displaying inhibitory peptides to essential 
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cytosolic enzymes, bioactivity of such peptides cannot be ascertain within this context. 
Therefore, a general strategy utilized for bioactivity screening of LpxD-binding peptides 
identified from phage display was worked out (Figure 3.2, panel b). A low copy, tightly 
controlled expression construct was employed to promote stringent conditions for 
bioactivity assays. DNA oligonucleotides, coding for the 17 peptides identified in the 
phage display screen were cloned into a low-copy (p15A ori) plasmid, pUMRJ100, 
upstream of the thioredoxin (trxA) coding region (Figure 3.3). The expression of the 
peptide-TrxA fusions were under the control of the L-arabinose promoter (ParaBAD). The 
resultant constructs were pooled and transformed into E. coli XL-1 Blue cells and 
selected on LB-chloramphenicol (LB-cam) plates containing dextrose to suppress basal 
expression of the peptide fusions from the araBAD promoter. Individual colonies were 
then re-streaked onto both LB-cam/dextrose (non-induction) and LB-cam/L-arabinose 
(induction) plates to probe for toxicity (Figure 3.2, panel c).  No toxicity was seen on 
dextrose containing media. However, individual constructs expressing peptides 
RJPXD31, RJPXD33, or RJPXD34 displayed in vivo toxicity (no growth) when plated 
on LB-cam/arabinose media. These three peptides had a more extensive N/QXYMLP 
motif in common, again with variations in their respective aromatic and hydrophobic 
amino acids. Plasmids from random colonies not displaying toxicity were sequenced and 
demonstrated representation of all of the pooled constructs and proper orientation of the 





Figure 3.2. Identification and selection of bioactive peptides. a) Sequences of the peptides identified from 
phage display after rounds 3 and 4 of selection. The figure was generated by WebLogo 
(weblogo.berkeley.edu) subsequent to alignment in Clustal W. The size of the characters at any given 
position denotes the frequency of an amino acid, while the height of the stack is indicative of sequence 
conservation. b) Outline of bioactivity screen for peptides from phage display:  E. coli XL1 Blue was 
transformed with a pool of plasmids coding for the expression of peptides identified from phage display 
(under the control of the ParaBAD) and evaluated under peptide induction and non-induction conditions. c) 
Representative replica plates from bioactivity screen: LB-Dextrose (non-induction of peptide), LB-
Arabinose (induction of peptide).  Red circle indicates no growth of bacteria upon in vivo peptide 
expression. 
 
Figure 3.3. Bioactivity screening plasmid.  Peptide coding sequences identified from phage display were 
cloned separately into the NdeI/ApaI sites of pUMRJ100.  Upon induction with L-arabinose in E. coli XL1 
Blue the cloned peptides are expressed as protein fusions with thioredoxin. 
 
Purified native LpxA and His6-LpxD, which has been shown in literature to 
exhibit equal activity to wild-type LpxD, were used in peptide binding studies (1). The 
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binding of fluorescein-labeled peptide to acyltransferase was assessed by measuring the 
changes in fluorescence polarization, which reflects changes in polarization of emitted 
light due to the differences in mobility between free and protein bound fluorescein-
labeled peptide, when excited by polarized light.  RJPXD33 was chosen for fluorescent 
labeling because of its bioactivity and disproportioned representation among the 
randomly selected phage.  Increasing concentrations of acyltransferase, in the presence of 
fixed [FITC-RJPXD33], resulted in a sigmoidal binding isotherm upon plotting 
fluorescence polarization (mP) versus Log [acyltransferase]. FITC-RJPXD33 exhibited a 
Kd = 607 ± 40 nM for His6-LpxD with a mP = 295 ± 3 (Figure 3.4, panel a). While in 
the presence of LpxA, FITC-RJPXD33 exhibited a Kd = 20 ± 1.5 M and a mP of 254 ± 
3. As a negative control experiment, FITC-RJPXD33 was tested against E. coli MurA, 
UDP-N-acetylglucosamine enolpyruvyl transferase, under the same conditions as with 







Figure 3.4. Direct and competetion binding data for bioactive peptides. a) Binding plot showing binding of 
FITC-RJPXD33 to both LpxD and LpxA. FITC-RJPXD33 was held constant at 20 nM while LpxD or 
LpxA were titrated at increasing concentrations to determine the binding isotherms. b) A fluorescent, 
competition LpxD binding assay, in which FITC-RJPXD33 (20 nM) and LpxD (660 nM) were held 
constant while unlabeled competing ligand (RJPXD33 (blue), P920 (red), or R-3-OH-myristoyl-ACP 
(green)) was titrated at various concentrations. P920 did not demonstrate binding to LpxD. All data points 
represent the mean of three individual experiments with error bars representing the standard deviation. The 
relative amount of bound labeled peptide was normalized by dividing the mP obtained in the presence of 
competing ligand by the mP obtained in the absence of competing ligand. 
 
Competition binding experiments against unlabeled peptides were also carried 
out.  In these experiments, the ability of labeled peptide to bind to acyltransferase, at 
varying concentration of unlabeled peptide, was ascertained. RJPXD33 was able to 
compete against FITC-RJPXD33 for binding to His6-LpxD (Kd = 6.5 ± 0.2 M; Figure 
3.4, panel b) and against FITC-P920 for binding to LpxA (Kd = 22 ± 2.1 M; Figure 3.5 
panel a).  RJPXD31 and RJPXD34 were able to displace FITC-RJPXD33 from LpxD as 
well, with Kds of 41 ± 3 M and 31 ± 1.5M, respectively (Table 3.2; Figure 3.5, panel 
c).  The binding of these two peptides to LpxA were weaker than that of RJPXD33, with 
RJPXD31 displaying Kd = 119 ± 9 M, while RJPXD34 did not bind at concentrations up 
to 300 M (Figure 3.5, panel b). Unlike the LpxD-binding peptides, FITC-P920 showed 
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binding to LpxA, Kd = 187 ± 19 nM, mP = 269 ± 3, but did not bind to His6-LpxD at 
concentrations up to 50 M.  Unlabeled P920 demonstrated a Kd of 4.7 ± 0.2 M for 
LpxA (Figure 3.5, panel a), but could not compete against FITC-RJPXD33 for binding to 
His6-LpxD (Figure 3.4, panel b), as evidenced by no decrease in polarization at 
concentrations up to 300 M of unlabeled P920. 
 
Figure 3.5. Competition FP assays with unlabeled ligands. Panel a unlabeled RJPXD33 and P920 were 
competed against FITC-P920 for binding to LpxA. In panel b, unlabeled RJPXD31 and RJPXD34 were 
competed against FITC-P920 for binding to LpxA. In panel c, RJPXD31 and RJPXD34 were competed 
against FITC-RJPXD33 for binding to LpxD. 
  The above results underscore the unique nature of peptides identified herein. 
Each of the bioactive peptides identified in this study bound to LpxD with dissociation 
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constants in the range of 6-40 M. Despite the sequence similarities however, our studies 
show that RJPXD34 is specific for binding to LpxD, showing no binding to LpxA, while 
RJPXD31 and 33 show affinity for LpxD as well as LpxA. Those peptides having affinity 
for both acyltransferases bound approximately three times more tightly to LpxD than to 
LpxA, which is expected since they had been identified from biopanning against LpxD. 
Interestingly, the FITC-labeled RJPXD33 bound approximately thirty times more tightly 
to LpxD than to LpxA.  While labeled RJPXD33 had the same affinity as the unlabeled 
peptide to LpxA, the labeled peptide bound ten times tighter than the unlabeled peptide to 
LpxD. This may indicate that the -alanyl-fluorescein moiety is making more extensive 
interactions within LpxD. 
Bioactive peptides were then tested for their abilities to interfere with substrate 
binding and acyltransferase activity. Inhibition of enzyme activity was determined for our 
highest affinity dual binding peptide (RJPXD33) and our LpxD-specific peptide 
(RJPXD34), using a recently described fluorescent acyltransferase assay (Table 3.2; 
Figure 3.6). RJPXD33 displayed IC50s of 3.5 ± 0.08 M and 19 ± 1.2 M against LpxD 
and LpxA, respectively, which were consistent with the relative binding affinities of the 
unlabeled peptide for each of the acyltransferases (above). Likewise, RJPXD34 had an 
IC50 of 26 ± 3.0 M against LpxD and did not inhibit LpxA. Next, competition binding 
experiments against acyl-ACP substrate was carried out. In this experiment the ability of 
labeled peptide to bind to acyltransferase in the presence of substrate was ascertained. 
Utilizing FITC-RJPXD33 as our tracer, R-3-hydroxymyristoyl-ACP shows competitive 
binding with labeled peptide to LpxD, with a dissociation constant of 8.8 ± 0.7 M 
(Figure 3.4, panel b). This binding constant for acyl-ACP was in good accordance with 
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the published Km value for acyl-ACP to LpxD (1). As a control, fluorescein-labeled 
RJPXD33 was evaluated for binding to 50 M holo-ACP or acyl-ACP alone and 
displayed no significant increase in fluorescence polarization, indicating that the peptide 
was not binding to ACP. Recent kinetic characterization of E. coli LpxD described an 
ordered mechanism where acyl-ACP binding is the initial event (1).  Peptides in this 
study were also selected to bind to the unbound form of LpxD and our binding studies 
show that RJPXD33 binds to LpxD in a mutually exclusive manner with R-3-
hydroxymyristoyl-ACP, representing a potential basis for its inhibitory activity.  
Likewise, RJPXD33 binds to LpxA in a competitive fashion with P920, which has 
previously been shown to be a competitive inhibitor of LpxA with respect to R-3-
hydroxymyristoyl-ACP (2).  These observations are consistent with other studies in 
which randomly selected phage-bound peptides have been shown to bind to “hot spots” at 
proteinprotein or proteinligand interfaces (17,18). 
Table 3.2. Binding constants of labeled and unlabeled peptides for acyltransferases.  







TNLYMLPKWDIP-NH2 (RJPXD33) 6.5 ± 0.2 ± 22 ± 2.1 (19 ± 1.2) 
FITC-(a)TNLYMLPKWDIP-NH2 (FITC-RJPXD33) 0.6 ± 0.04  17 ± 1.6 
SENNFMLPLLPL-NH2 (RJPXD34) 31 ± 1.5± DNB 
QHFMVPDINDMQ-NH2 (RJPXD31) 41 ± 3 119 ± 9 
SSGWMLDPIAGKWSR (P920) DNB 4.7 ± 0.2 
FITC-(a)SSGWMLDPIAGKWSR-NH2 (FITC-P920) DNB 0.19 ± 0.02 
a - -alanine used for the N-terminal labeling with FITC.  DNB – Did Not Bind. Binding constants for 
FITC labeled peptides were obtained from direct binding experiments as described in Methods. Binding 
constants for non-labeled peptides were obtained from competition binding experiments against FITC 






Figure 3.6. IC50 determination of RJPXD33 and RJPXD34. Measurements were performed in accordance 
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Where vi is the initial velocity in the presence of inhibitor, vo is the initial velocity in the absence of 
inhibitor, [I] is the concentration of inhibitor, IC50 is the concentration of inhibitor at 50% inhibition, and h 
is the hill slope. IC50’s were determined a) for RJPXD33 (blue) and RJPXD34 (purple) against LpxD and 
b) for RJPXD33 (blue) against LpxA. RJPXD34 displayed no inhibition of LpxA at concentrations up to 
200 M. Data points represent the mean of three individual experiments and error bars represent the 
standard deviation. 
 
Overexpression of an essential enzyme to suppress the toxicity of an antibacterial 
agent is a validated strategy used to identify subcellular targets (19-21). This multicopy 
suppression strategy was adopted to determine whether or not the antibacterial activity 
displayed by peptides identified in this study were due to inhibition of LpxD in vivo. 
Again, for this evaluation the most potent dual binding peptide, RJPXD33, as well as the 
LpxD-specific peptide, RJPXD34 were assessed in cells containing pUC18 or 
pUC18::lpxD. As seen previously, induction of peptide fusions alone expressing 
RJPXD33 or RJPXD34 showed no growth. However, as expected, suppression of 
antibacterial activity was seen upon induction of peptide fusions in cells containing 
additional extrachromasomally expressed LpxD resulting in bacterial growth (Figure 
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3.7). These data are consistent with the in vitro binding and inhibition studies and 
indicate that the bioactive LpxD-binding peptides primary mode of antibacterial activity 
is due to inhibition of LpxD. The stronger LpxD affinity along with the weaker LpxA 
binding affinity of RJPXD33 may account for the fewer number of colonies observed in 
the LpxD overexpression strain, as compared to RJPXD34.   
 
Figure 3.7. In vivo bioactivity assay. (A). Cells containing pUMRJ100::RJPXD33 (XD33) or 
pUMRJ100::RJPXD34 (XD34) were plated on LB-dextrose (1.0% w/v) or (B) on plates containing LB-
arabinose (0.2% w/v). (C) Cells containing pUC18::lpxD and the peptide fusion constructs were further 
plated on LB-arabinose to demonstrate that over-expression of LpxD could suppress the toxicity induced 
by the peptide fusions. 
 
In conclusion, the LpxD N-acyltransferase is an essential enzyme of lipid A 
biosynthesis and has been touted as a novel subcellular target for antimicrobial 
development (1). The toxicity associated with the expression of LpxD-binding peptides in 
E. coli in this current study serves as the first example of in vivo chemical inhibition of 
LpxD activity and further validates LpxD as an antibiotic target. With the continuing rise 
in resistance to current antimicrobial chemotherapy, much interest exists in finding new, 
less resistance-prone ways to inhibit bacterial growth. An underexplored, yet promising, 
niche in the field of antimicrobial development is the targeting of multiple essential 
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proteins with a single antimicrobial agent (22,23). Such unique agents require an 
organism to obtain multiple mutations in several essential targets in order to display 
clinically relevant resistance (24). With the identification of RJPXD33, the targeting of 
the structurally and functionally similar acyltransferases, LpxA and LpxD may provide 
another such opportunity. Moreover, protein•ACP interaction inhibitors directed against 
bacterial Type II ACP-dependent acyltransferases represent an untapped area for the 
development of unique protein•protein interaction inhibitors as potential antibacterial 
agents. Finally, this work has identified novel peptides that can serve as surrogate ligands 
for both LpxA and LpxD. Surrogate ligands such as these can serve as templates for the 
development of peptidomimetic based compounds more amenable to chemotherapeutic 
drug delivery. Furthermore, such peptides can be used to develop fluorescent binding 
assays, such as described above, to facilitate biological screening activities for the 
identification of small molecule acyltransferase inhibitors. 
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Structural and Biochemical Characterization of the Dual Targeting Acyltransferase 
Inhibitor of Lipid A Biosynthesis  
An inhibitor (RJPXD33; TNLYMLPKWDIP-NH2) was recently identified that 
demonstrated affinity for both LpxD and LpxA (1). While peptides display susceptibility 
to proteases and poor bioavailability, they have become a coveted tool in chemists and 
biologists repertoires, owing to the ease of synthesis and functional utility. Thus much 
attention has been given to the strategies or designing of “peptide mimics”, or 
peptidomimetics, that display greater bioavailability, enhanced three dimensional 
structural characteristics and proteolytic stability compared to their natural counterparts 
(2). However, a structural and biochemical understanding of how the peptide interacts 
with its host complex is crucial to the development of peptidomimetics.  
The molecular mechanism by which RJPXD33 interacts with either LpxA or 
LpxD is currently unknown. Herein, we have utilized x-ray crystallography and peptide 
photo-affinity probes to provide insights into the binding interactions between the 
acyltransferases and RJPXD33. Furthermore, acyltransferase binding studies utilizing 
truncations of RJPXD33 were undertaken in order to identify the minimal sequence 
necessary to inhibit both LpxA and LpxD, as well as to provide biochemical verification 






 Materials. Bio-Rad Protein assay and BioGel P2 size exclusion gel were 
purchased from Bio-Rad. LB (Lenox) broth and agar were purchased from Difco. 
Fluorescein isothiocyanate (FITC) was purchased from Acros Organics. Natural amino 
acids, Rink Amide Resin and Fmoc-OSu were purchased from Anaspec. Fmoc-4-Azido-
L-phenylalanine was purchased from Chem-Impex. Photo-leucine (PhotoLeu) and HPDP-
Biotin were purchased from Thermo Fisher/Pierce. Benzonase was purchased from 
Novagen. Trypsin Gold was purchased from Promega. MS grade GluC was purchased 
from Roche. All buffers and antibiotics were purchased in the highest grade from Sigma 
Aldrich or Fisher Scientific.  
 Protein Crystallography. Protein purification was carried out as previously 
described (3). Prior to crystallization, purified LpxA (10 mg/mL) was incubated for 1 h at 
4 °C in the presence of 600 M RJPXD33 (final concentration of DMSO was 2% v/v). 
The mixture was centrifuged at 10,000 xg for 10 min at 4 °C to pellet any insoluble 
material. Crystals were grown by vapor diffusion in a sitting drop tray. Droplets 
contained 2 L of the LpxA-RJPXD33 solution and 2 L of a well solution containing 
0.8 – 1.8 mM Phosphate buffer (pH 6.3 – 6.8) and 31 – 34 % DMSO. Crystals formed 
within 24 h. Crystals were cryoprotected in well solution containing 20% glycerol and 
flash frozen in liquid nitrogen. X-ray data was collected at LS-CAT ID-21-F and –G lines 
at the Advanced Photon Source at Argonne National Laboratory. Data was processed 
using HKL2000 software (4). The complex was solved by molecular replacement with 
Phaser (5) using a previously solved structure of LpxA (containing no ligands; pdb 
1LXA) as the starting model (6). Iterative rounds of refinement and model building were 
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completed using Buster (7) and Coot (8). MolProbity (9,10) and Parvarti (11) were used 
to validate the structures. Figures were generated in PyMol (Schrödinger LLC). The 
LpxA-RJPXD33 data collection and refinement statistics are given in Table 4.1. 
 Fluorescence Polarization (FP) Assay. Peptides were synthesized as previously 
reported for solid phase peptide synthesis (12). The FP assay was performed as 
previously described (1). In 384-well black Costar plates, LpxA or His6-LpxD were 
serially diluted while holding the fluorescent peptide at 20 nM in a final volume of 50 L 
in 20 mM HEPES pH 8.0 (~0.01% DMSO). The wells were gently mixed and incubated 
at 30 °C in the dark for 15 min. Polarization was measured on a SpectraMax M5 plate 
reader in triplicate with readings taken at ex = 485 nm and em = 525 nm. The binding 
data was first fit to a standard binding isotherm (eq 1): 
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(1) 
where mP is the experimentally determined polarization, mPf is the polarization of free 
FITC-RJPXD33, [P] is the total acyltransferase concentration, Kd is the dissociation 
constant of peptide-protein complex, and mPb is the polarization value of fully bound 
fluorescent peptide. The calculated mPb was used to normalize the experimental data to 
fit the binding curves to the Hill equation (eq 2), where a is the fraction of FITC-peptide 
bound, h is the Hill coefficient, [P] is the total concentration of acyltransferase, and Kd is 
















 For competition binding assays, 220-660 nM of acyltransferase was incubated in 
the presence of varying concentrations of unlabeled peptides or acyl-ACP for 10 min at 
30 °C in the dark. The [I]50 was determined from the competition binding curve and the 
dissociation constant of unlabeled ligand was calculated as previously described (13) 
using eq. 3: 
 
   
     
     
  
 





where [I]50 is the unlabeled peptide concentration (inhibitor) at 50% inhibition, [L]50 is 
the free ligand (fluorescent tracer) concentration at 50% inhibition, [P]0 is the free protein 
concentration at 0% inhibition, Kd is the dissociation constant of fluorescent peptide 
(tracer), and Ki is the calculated dissociation constant for unlabeled peptide. 
 Fmoc-Photoleucine. Fmoc-PhotoLeu was synthesized as previously described 
(14). In an aluminum foil covered round bottom flask, PhotoLeu (1.4 mmol, 200 mg) and 
sodium bicarbonate (2.8 mmol, 236 mg) were dissolved in 20 mL of H2O and chilled to 0 
°C on ice. Fmoc-OSu (2.1 mmol, 708 mg) was dissolved in 10 mL of THF and dropwise 
added over 15 min to the covered round bottom flask. The resulting slurry was stirred on 
ice for 10 min and then allowed to warm to room temperature for 8 h. The flask was 
placed on ice and the reaction was stopped by addition of 25 mL of H2O and 50 mL ethyl 
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acetate (EtOAc) followed by acidification to pH 2 with concentrated HCl. The product 
was extracted (3x) with 50 mL EtOAc and concentrated by rotary evaporation. The 
resulting white solid was purified by flash chromatography with 1% methanol (v/v) and 
1% acetic acid (v/v) in dichloromethane.  The product was obtained as a white solid (464 
mg, 91%). 1H NMR (400 MHz, DMSO) d 12.70 (s, 1H), 7.87 (d, J = 7.5, 2H), 7.71 (dd, J 
= 7.6, 4.4, 3H), 7.39 (t, J = 7.4, 2H), 7.30 (t, J = 7.4, 2H), 4.38 - 4.16 (m, 3H), 3.89 - 3.76 





, 388.1278; observed 388.1276. 
 Biotinylation of Photo-affinity Peptides. Purified peptides (~2–3 mg) were 
resuspended in 50% DMF/10% ACN/0.1% TFA at a concentration of 0.4 mM. HPDP-
Biotin was added to a concentration of 0.8 mM and the solutions were incubated 
overnight (~16 h) at 37 °C (15). The resulting mixture was purified by RP-HPLC, 
lyophilized and confirmed by high resolution ESI-MS. 
Covalent Cross-linking of RJPXD33 Photo-affinity Probes to LpxD. Photo-
activatable peptides (24 M) were incubated with LpxD (10 M), in the presence or 
absence of unlabeled peptide (150 M) in 96-well half-area clear plates on ice in a final 
volume of 30 L in 20 mM HEPES pH 8.0 (DMSO 1% v/v). Plates, remaining on ice, 
were irradiated using a UV lamp (UVP model UVGL-58) at  = 365 nm for 10 min at a 
distance of ~2 cm. Samples were subsequently loaded and run on a 12% Tris-glycine 
SDS-PAGE gel. Gels were washed three times for 20 min at room temperature with 
deionized water to remove SDS. For fluorescein-labeled peptides, gels were analyzed for 
in-gel fluorescence using a Typhoon 9400 imaging system set to fluorescein wavelength 
(ex = 485 nm and em = 525 nm), PMT sensitivity at 500 and pixel size at 50 microns. 
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The resulting data was visualized using ImageQuant 5.2 software (RSBS-ANU). 
Following in-gel fluorescence analysis, gels were stained using SimplyBlue SafeStain 
(Invitrogen). 
 Peptide Enrichment for MS Analysis. Biotin-Photopeptides (200 M) were 
incubated on ice with LpxD (10 M) in a final volume of 500 L and cross-linked as 
described above. Excess biotin-Photopeptide was removed by ultrafiltration in a 
Microcon YM-10 concentrator (Millipore) and subsequent washing (5x) with 500 L of 
100 mM (NH4)HCO3 pH 7.8. The concentrated fractions (~100 L) of biotin-
Photopeptide 1 and 3 were digested (per manufacturer’s protocol) with TrypsinGold 
(Pierce), while biotin-Photopeptide 4 was digested with GluC (Roche). GluC digestion 
was necessary to avoid loss of the biotin-tag in Photopeptide 4 owing to an inherent 
trypsin site upstream of the cross-linking site. Digestions were carried out at 37 °C for 5 h 
and reactions were stopped by heating at 70 °C for 20 min followed by vortexing 
multiple times. Samples were loaded onto Streptavidin-conjugated DynaBeads 
(Invitrogen) with 1 h incubation at room temperature. The beads were washed (6x) with 
100 mM (NH4)HCO3 pH 7.8 (500 L) to remove unbound peptide. Bound peptides were 
eluted by incubating the beads in 100 mM (NH4)HCO3, 100 mM DTT pH 7.8 at 37 °C 
for 1 h (2 x 150 L). Samples were speed vacuum dried, brought up in 50 L of H2O and 
frozen at -80 °C until analyzed by MS. 
 Results 
 The co-crystal structure of LpxA•RJPXD33 (TNLYMLPKWDIP-NH2) diffracted 
to a resolution of 1.9 Å. The structure was solved by molecular replacement using a 
previously solved structure of LpxA (PDB code 1LXA), containing no ligands, as the 
69 
 
model structure (6). The structure was refined to an Rfactor and Rfree of 0.179 and 0.188, 
respectively, while maintaining a good MolProbity score and low clash score (9). The 
complete crystallography and refinement statistics can be found in Table 4.1. 
One molecule of LpxA and RJPXD33 occupied the asymmetric unit. However, 
three asymmetric units form around a 3-fold crystallographic axis, which is in agreement 
with other structures and previous data showing that LpxA is a homotrimer (16-18). 
Consistent with other structures, all of the 262 amino acids of LpxA, with the exception 
of the first methionine side chain, were visible in the electron density map. The N-
terminus of RJPXD33 binds within the region between two monomeric subunits, 
constituting the LpxA active site, with a portion of the M5 side chain missing (19). The 
six N-terminal amino acids of RJPXD33, TNLYML, run vertically up the bifurcated 
active site with T1 positioned at coil 6 of LpxA LH and L6 at coil 10. Three parallel  
strands make up one LH coil. The side chains of T1, L3, and M5 all point inward 
toward the hydrophobic cleft between parallel  strand 3 (PB3) of the LpxA subunit 
within the asymmetric unit and PB2 of the adjacent subunit. The side chains of Y4 and 
L6 occupy separate hydrophobic pockets along PB2 of the adjacent subunit, while the N2 
side chain makes a favorable amide- center stacked interaction with the Y4 side chain 
(20,21).  The density of the C-terminal six amino acids of RJPXD33 could not be 
visualized in the structure (Figure 4.1A and B) most likely due to the protrusion of this 






Table 4.1: Crystallography data collection and refinement statistics 
Data Collection    
SpaceGroup  P 213 
Unit Cell  a, b, c 
(Å) 
 96.40, 96.40, 96.40 
Wavelength (Å)  0.97872 
Resolution (Å)
1
  1.9 (1.93 1.90) 
Rsym  (%)
2
  5.7 (29.7) 
<I/sI>
3





 99.9 (100) 




Resolution (Å)  1.90 
R-Factor (%)
5
  0.179 
Rfree (%)
6
  0.188 









   
   Bonds  0.010 








  4.24 
1
Statistics for highest resolution bin of reflections in parentheses. 
2
Rsym =hj l Ihj-<Ih> l /hjIhj, where Ihj  is the intensity of observation j of reflection h and <Ih> is the 
mean intensity for multiply recorded reflections. 
3
Intensity signal-to-noise ratio. 
4
Completeness of the unique diffraction data. 
5
R-factor = h I IFoI – IFcI I / hIFoI, where Fo and Fc are the observed and calculated structure factor 
amplitudes for reflection h. 
6
Rfree is calculated against a 10% random sampling of the reflections that were removed before structure 
refinement. 
7
Root mean square deviation of bond lengths and bond angles. 
8






Figure 4.1. Crystal structure of RJPXD33 bound to LpxA. A. Crystal structure of RJPXD33 (magenta; 
spheres) in complex with LpxA (gray, surface map). Only the first six residues of RJPXD33 are modeled 
into the figure. RJPXD33 binds between two monomeric subunits of the trimer; only one molecule of 
RJPXD33 is shown. B. The 2Fo-Fc electron density map of the RJPXD33•LpxA complex contoured to 1 
around RJPXD33 (magenta; stick) with amino acids from LpxA (gray; stick) that surround the bound 
ligand. Though the full density of the methionine side chain from RJPXD33 could not be visualized, 
His160 of LpxA kinks away from the hydrophobic cleft allowing space for the methionine side chain to 
occupy the binding pocket. 
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RJPXD33 binds to LpxA in a unique fashion when compared to P920, despite a 
similar primary sequence motif (YMLP v. WMLDP) between the two (22). P920 forms a 
-hairpin fold where the head of the loop, isoleucine, occupies the hydrophobic cleft of 
LpxA and the N and C-termini face out of the pocket towards the solvent face (16). The 
backbone and side chains of P920 overlap into the UDP binding region when compared 
to the UDP-GlcNAc and UDP-3-O-(R-3-hydroxyacyl)-GlcNAc structures (17,23). In 
contrast, RJPXD33 has more of an extended conformation and occupies more of the 
hydrophobic fatty acid binding cleft, while demonstrating only a minimal overlap 
between the N2/Y4 side chains and the UDP binding site.  
The hydroxyl moiety of the T1 side chain of RJPXD33 forms polar contacts with 
H122, Q73, and an active site water of LpxA. These moieties have been implicated as 
binding contacts to the R-3-hydroxymyristoyl moiety of UDP-3-O-(R-3-
hydroxymryistoyl)-GlcNAc, the LpxA product (17). When the structures of RJPXD33 
bound EcLpxA and the EcLpxA with bound product (PDB 2QIA) were superimposed, 
the T1 -hydroxyl group was shown to occupy the same space as the R-3-hydroxy 
functional group of the myristate chain (Figure 4.2A and B).  In addition to the T1 
residue, the L3 and M5 side chains of RJPXD33 also occupy the fatty acyl binding 
region.  
The co-crystal structure of EcLpxA•RJPXD33 was also superimposed onto the C-
chain of the Leptospira interrogans LpxA-(R-3-hydroxylaurate)-methyl-
phosphopantetheine co-crystal structure (Figure 4.2C and D; PDB 3I3A) (24). While 
phosphopantetheine (PPan), the post-translational modification necessary for acyl chain 
assembly on ACP, derivatives are not substrates for EcLpxA or EcLpxD, R-3-hydroxy-
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lauryl-methyl-PPan has been shown to be a substrate for LiLpxA  (24,25). The PPan 
moiety of the LiLpxA structure was modeled as two conformations due to the electron 
density obtained from the complex. As seen with the EcLpxA•Product structure, the T1, 
L3, and M5 side chains of RJPXD33 overlay with the laurate chain of the LiLpxA 
structure. While RJPXD33 had minimal overlap with the UDP-GlcNAc functionality in 
the EcLpxA•product structure, the peptide backbone of RJPXD33 occupied the same 
space as the acyl-PPan substrate (conformation 1). This was highlighted at the amide 
bond between T1 and N2 of RJPXD33, which superimposes almost identically with the 
thioester bond between the acyl-chain and the PPan moiety.  
Of the four complexes named above, all except the P920•LpxA complex 
contained a H160 (H155 of LiLpxA) residue that kinked outward, towards the solvent 
front. The opposite was true for H160 which faces the hydrophobic pocket in the 
structures of the free form of LpxA (PDB 1LXA; the molecular replacement model), and 
complexes bound with UDP-GlcNAc (PDB 2JF3) or inhibitory peptide 920 (PDB 2AQ9) 
(6,16,23). These results demonstrated that H160 of LpxA must kink outwards in a 
conformational change to allow the peptide or fatty acyl chain to access the hydrophobic 
cleft. While the full electron density of the RJPXD33 M5 side chain cannot be accounted 
for, these results would suggest that M5 would occupy the binding region formed when 




Figure 4.2. A. The RJPXD33•LpxA (magenta-gray) complex overlain against the UDP-3-O-(R-3-
hydroxymyristoyl)-GlcNAc•EcLpxA complex (PDB 2QIA;yellow-pink) (27). RJPXD33, UDP-3-O-(R-3-
hydroxymyristoyl)-GlcNAc, and certain side chains of LpxA (H160, H122, H99, Q73) are shown in stick 
diagram. The active site water which hydrogen bonds to -hydroxymryistate and H99 is shown as a sphere 
(red). B. A zoomed in view of the ligands RJPXD33 (magenta) and UDP-3-O-(R-3-hydroxymyristoyl)-
GlcNAc (yellow). Residues of RJPXD33 are labeled in red while UDP-3-O-(R-3-hydroxymyristoyl)-
GlcNAc are labeled in black. The -hydroxy of the threonine side chain of RJPXD33 occupies the same 
space where the -hydroxy of the myristate side chain of the LpxA product is located. Furthermore, the 
Leu3 and Met side chains of RJPXD33 seem to occupy the hydrophobic cleft between two monomeric 
subunits, normally where the acyl chain of the LpxA product or acyl-ACP are suggested to bind. C. The 
RJPXD33•EcLpxA (magenta-grey) complex overlain against the (R-3-hydroxylaurate)-methyl-
phosphopantetheine•LiLpxA complex (PDB 3I3A; green-cyan) (24). As in Figure 3A ligands, the active 
site water and certain side chains are shown in stick diagram. Residues in parenthesis represent the amino 
acid numbering for L. interrogans LpxA. D. A zoomed in view of the ligands RJPXD33 (magenta) and (R-
3-hydroxylaurate)-methyl-phosphopantetheine (PPan). PPan was modeled into two conformations in its 
original structure (24). The Leu3 and Met side chains of RJPXD33 occupy the hydrophobic pocket in 
which the R-3-hydroxylaurate occupies, similar to the product complex. The amide bond between Thr and 
Asn of RJPXD33 overlay almost identically to the thioester bond between PPan and R-3-hydroxylaurate, 




 In order to validate our crystal structure and evaluate the potential for possible 
truncations, FITC-RJPXD336 was synthesized. FITC-RJPXD336 lacks the six 
terminal amino acids of full length FITC-RJPXD33. Fluorescence polarization (FP) 
experiments using wild-type LpxA and His6-LpxD were performed to quantitate the 
binding affinity of the truncated RJPXD33 peptide (Figure 4.3). When the assay was 
performed with LpxA, the observed Kd for FITC-RJPXD336 was 12 + 1 M (Table 2). 
This value was in close proximity to the previously published value (Kd = 18 + 1.6 M) 
for the full length FITC-RJPXD33. This suggested that the six terminal amino acids were 
not making extensive binding contacts to LpxA, further validating the crystal structure. 
 
Figure 4.3. FITC-RJPXD336 binding isotherm against LpxA and LpxD. FITC-RJPXD336 (FITC-(A)-
TNLYML-CONH2) was held constant (20 nM) while varying concentrations of LpxA or LpxD were 
titrated to generate the binding isotherm. FITC-RJPXD336 demonstrated no loss of binding affinity to 
LpxA (Kd = 12 + 1 M), when compared to FITC-RJPXD33. This suggests that the 6 C-terminal residues 
are not making binding contacts with LpxA which is in agreement with the crystallographic data observed. 
However, a significant loss of affinity for FITC-RJPXD336 was observed (Kd = 22 + 1 M) with respect 
to LpxD, suggesting that the 6 C-terminal amino acids are important for binding to LpxD. Affinities were 





 To evaluate whether RJPXD33 bound to LpxD in a similar fashion, FITC-
RJPXD336 was tested against His6-LpxD. FITC-RJPXD336 demonstrated a binding 
affinity of Kd = 22 + 1 M. This was approximately a 30-fold decrease (FITC-RJPXD33 
Kd = 0.6 + 0.04 M) in binding affinity compared to the full length peptide, suggesting 
the C-terminal residues were making substantial binding interactions to LpxD (1). 
 Unlabeled truncations of RJPXD33 were evaluated using a competition binding 
assay to identify the minimal sequence motif necessary for binding to LpxA and LpxD 
(Table 4.2). C-terminal truncations lacking 5, 6 or 7 amino acids demonstrated Kd’s 
against LpxA equal to 18.6 + 3.5 M, 30.4 + 2.8 M or > 100 M (Table 4.2). 
Truncations beyond the 7
th
 amino acid displayed no appreciable binding to LpxA at 
concentrations up to 200 . RJPXD33C5 demonstrated a binding affinity of 20.8 + 
1.6 M to LpxD. RJPXD33C6 bound weakly to LpxD, and C-terminal truncations 
beyond the 6
th
 amino acid demonstrated no appreciable binding at concentrations up to 
200 M. These results correlated well with the direct FP binding data. 
 N-terminal truncations were also synthesized and tested against both LpxA and 
LpxD. A single truncation of RJPXD33 at the N-terminus completely abolished any 
binding to LpxA. Interestingly, RJPXD33N1, RJPXD33N2 and RJPXD33N3 
displayed binding affinities for LpxD equal to 1.6 + 0.2 M, 2.8 + 0.4 M and 15.3 + 1.5 
M (Table 4.2). Truncations beyond the 3
rd
 amino acid did not bind to LpxD.  
These results suggested that the C-terminus of RJPXD33 was making extensive 
binding contacts to LpxD, but not to LpxA. While the first two N-terminal truncations did 
not adversely affect binding to LpxD, the lack of T1 completely ablated any affinity for 
LpxA. However, deletion of amino acids within RJPXD33’s –YMLP– motif, a conserved 
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sequence motif identified for LpxD and LpxD/LpxA dual binding peptides (1), proved to 
be detrimental for binding to either target. 
Table 4.2. Peptide sequences and binding affinity data for LpxD and LpxA. 





Direct Binding Assay 
   
 
FITC-RJPXD336 FITC--TNLYML 22 + 1 12 + 1 
 
FITC-Photo 1 FITC--TNXYMLPKWDIP 2.1 + 0.3 N.T. 
 
FITC-Photo 2 FITC--TNLZMLPKWDIP D.N.B. N.T. 
 
FITC-Photo 3 FITC--TNLYMXPKWDIP 1.1 + 0.1 N.T. 
 
FITC-Photo 4 FITC--TNLYMLPKWDXP 0.8 + 0.1 N.T. 
Competition Binding Assay 
   
 
RJPXD33N1 NLYMLPKWDIP 1.6 + 0.2 D.N.B. 
 
RJPXD33N2   LYMLPKWDIP 2.8 + 0.4 D.N.B. 
 
RJPXD33N3    YMLPKWDIP 15.3 + 1.5 N.T. 
 
RJPXD33N4     MLPKWDIP D.N.B. N.T. 
 
RJPXD33C5 TNLYMLP 20.8 + 1.6 18.6 + 3.5 
 
RJPXD33C6 TNLYML > 95 30.4 + 2.8 
 
RJPXD33C7 TNLYM D.N.B. > 100 
  RJPXD33C8 TNLY D.N.B. D.N.B. 
 – -Alanine 
D.N.B – Did not bind 
N.T. – Not Tested 
Kd’s are calculated from IC50 binding isotherms as described in Materials and Methods. If the IC50 was 
determined to be greater than 200 M, the Kd’s were marked > than the calculated number for an IC50 of 
200 M. 
 
 Numerous attempts to crystallize LpxD with RJPXD33, FITC-RJPXD33, 
RJPXD336 or FITC-RJPXD336 were performed, but were ultimately unsuccessful. In 
order to further understand how RJPXD33 binds to LpxD, derivatives of FITC-RJPXD33 
containing a diazirine-based leucine derivative (14,26) or 4-azidophenylalanine were 
synthesized (Figure 4.4A). When irradiated with UV light these moieties can covalently 
cross-link to a bound protein, capturing the peptide-protein interaction. It was envisioned 
that a covalently linked peptide could be captured, trypsinized and the binding location 
could be mapped from LC/MS/MS analysis. 
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 In order to demonstrate that the photo-affinity label did not disrupt binding, FP 
experiments were performed with FITC-Photopeptide 1 – 4 against LpxD (Fig 4.4B). 
Peptides 1, 3 and 4 containing the diazirine moiety bound to LpxD with little to no loss in 
binding affinity (Table 4.2, Kd’s = 0.8 – 2.1 M). The 4-azidophenylalanine substitution 
for tyrosine was not tolerated, as Photopeptide 2 did not show an increase in polarization 
with increasing concentrations of LpxD. 
 Owing to its binding affinity, Photopeptide 4 was chosen to undergo studies for 
UV time dependence ( = 365 nm) and peptide concentration dependence of photo-
labeling (Figure 4.5A and B). In a final volume of 30 L, 10 M of LpxD and 6 M 
Photopeptide 4 were held constant while UV times were varied from 1 – 20 min. After 10 
min there was no appreciable increase in fluorescence labeling of LpxD. Thus, 10 min 
UV irradiation was used for the remainder of the in-gel fluorescence experiments. 
Concentration dependence of Photopeptide 4 was tested from 0.75 – 24 M while 
holding LpxD constant at 10 M. A concentration dependent increase in fluorescence can 




Figure 4.4. Photoactivatable peptides targeting LpxD. A. Peptide sequences containing the photo-
activatable diazirine-based leucine mimic, PhotoLeu (X), or 4-azidophenylalanine tyrosine mimic (Z). B. 
Fluorescence polarization experiments were performed holding FITC-labeled photo-activatable peptides 
constant (20 nM) while varying concentrations of LpxD. All of the PhotoLeu containing FITC-labeled 
peptides were able to bind LpxD with only a slight loss in affinity (Kd’s = 0.79 – 2.07 M) compared to the 
parent peptide, FITC-RJPXD33 (Kd = 0.6 M). However, the 4-azidophenylalanine containing peptide 
displayed no appreciable binding to LpxD up to ~10 M of LpxD. Affinities were determined from the 
mean of three individual experiments using the standard deviation as the calculated error. 
 
 Photopeptides 1, 3 and 4 (24 M) were subjected to UV irradiation in the 
presence of 10 M LpxD with and without 150 M of unlabeled RJPXD33 (Fig. 4.5C). 
When UV light was omitted no cross-linking occurred. However when the peptides and 
protein were irradiated with UV light peptides were covalently cross-linked to LpxD as 
visualized through in-gel fluorescence. Addition of unlabeled RJPXD33 significantly 
decreased the fluorescent signal indicating that the covalent cross-linking is due to 
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specific peptide•protein interactions and that the photopeptides are binding in a similar 
manner to the parent peptide. As a control, reactions containing LpxD without the 
Photopeptides were subjected to UV irradiation though no observable fluorescence was 
detected. 
 
Figure 4.5. In-gel fluorescence of photo-activatable peptides. A. Time dependence of photo-crosslinking of 
Photo 4 to LpxD. Photo 4 and LpxD were held constant at 6 and 10 M respectively while being irradiated 
with UV light (365 nm) for varying times. B. Concentration dependence of Photo 4. Concentrations of 
Photo 4 were varied while LpxD was held constant at 10 M while irradiating with UV light for 10 min. C. 
In-gel fluorescence while holding LpxD and Photo-activatable peptides constant at 10 and 24 M in the 
presence or absence of unlabeled RJPXD33 (150 M). LpxD was stained with simply blue safe stain to 
demonstrate loading was constant. 
 
Efficiency of photo cross-linking was approximated on a 1 mL scale as described 
in the materials and methods. Labeling efficiency of the FITC labeled photo-activatable 
peptides was 19%, 15.2% and 16.6% respectively for Photopeptides 1, 3 and 4. However, 
the FITC labeled Photopeptides could not be enriched enough to identify the binding 
regions via LC/MS. In order to provide enrichment of trypsinized peptides containing the 
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covalently linked RJPXD33 adducts, the FITC label was substituted for a cysteine-Biotin 
linked through a disulfide bond (Figure 4.6) (15).  MS experiments and analysis are 
currently being performed. 
 
Figure 4.6. Schematic of the linkage between biotin and the Photo-activatable peptides. One of the leucine 
(L) or isoleucine (I) residues is substituted for PhotoLeu (X) in each of the peptides.  – -Alanine. 
 
 Discussion  
Peptides and peptidomimetics have been used as antimicrobials, some of which 
target bacterial membranes, DNA and RNA or proteins (27-30). In order to design potent 
peptidomimetic compounds one needs a fundamental understanding of the molecular 
interactions between the peptide and target of interest. The RJPXD33-LpxA crystal 
structure has assisted in elucidating the mechanism of this peptide•protein interaction. 
RJPXD33 binds to LpxA in an unforeseen binding mode. Consistent with our peptide 
truncation studies, only the N-terminal six amino acids of RJPXD33 are seen in the 
crystal structure. The density of the rest of this peptide could not be visualized in the 
structure, indicating that the six C-terminal amino acids make no binding contacts to 
LpxA and are highly disordered.   
Though no LpxA•acyl-ACP structure is available, these current structures are 
suggestive that RJPXD33 would overlap with the acyl-PPan arm of acyl-ACP, thereby 
inhibiting acyl-ACP from binding to LpxA. This is in agreement with our previous results 
that demonstrated RJPXD33 was binding exclusive of acyl-ACP to LpxD and could 
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displace the E. coli LpxA inhibitory peptide 920 (P920; SSGWMLDPIAGKWSR) which 
was shown to be an acyl-ACP competitive ligand (1,16). While sequence similarity to 
P920 initially suggested that RJPXD33 may adopt a similar fold when compared to P920, 
the crystal structure clearly demonstrates a unique binding modality. Structural overlays 
of the RJPXD33•LpxA complex with UDP-3-O-(R-3-hydroxyacyl)-GlcNAc•EcLpxA 
and acyl-PPan•LiLpxA highlighted how the -hydroxy of T1 and hydrophobic side 
chains of L3 and M5 occupied the fatty acyl binding cleft. However, the amide bond 
between T1 and N2 mimicked the thioester bond of acyl-PPan, while the peptide 
backbone of RJPXD33 occupied similar space as the PPan moiety. These findings 
suggest that RJPXD33 mimics the acyl-PPan moiety of acyl-ACP. This similarity to the 
acyl-PPan most likely accounts for the dual targeting nature of RJPXD33 owing to the 
fact that both enzymes utilize acyl-ACP as a substrate. Considering the diverse array of 
protein•protein interactions between ACP and partner proteins, other acyl-PPan mimics 
may find use as antimicrobial inhibitors of ACP-protein interactions. 
 A conformational change in H160 of the RJPXD33•EcLpxA, UDP-3-O-(R-3-
hydroxyacyl)-GlcNAc•EcLpxA and acyl-PPan•LiLpxA structure can be seen, which 
differentiate them from other LpxA structures (17,24). While mutation of H160 to Ala 
reduced the activity to ~5% of the wild-type enzyme, the unfavorable nature of the LpxA 
reaction (Keq = 0.01) and limitations of the radioactive assay prevented definitive answers 
with regards to the involvement of this residue in enzyme catalysis (18,19). From their 
mutational study, Wyckoff and Raetz hypothesized that H160’s distance from the 
catalytic H125 residue (~12 Å) may indicate that it plays a role in substrate binding. 
Acidic amino acids of ACP have been implicated in binding to basic patches of partner 
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proteins, though there is no conserved binding motif among known ACP binding proteins 
(31). From previous modeling experiments, the predicted ACP binding site is within 
close proximity to the H160 residue, though the authors did not implicate it in binding 
(32). This study was also performed on apo-ACP lacking the PPan post-translational 
modification which may have caused subtle differences in binding to LpxA. This H160 
may be forming polar contacts with the acidic residues of acyl-ACP, and thus may be 
important in binding. With the increase in tools to study the LpxA•ACP interaction 
(1,33), this issue warrants further investigation and may elucidate additional amino acids 
necessary for acyl-ACP binding. 
The co-crystal structure of RJPXD33•LpxA and the FP experiments associated 
with FITC-RJPXD336 demonstrate that certain truncations can bind with minimal loss 
of affinity for LpxA. Such truncations would be important in developing smaller 
peptidomimetics capable of crossing the cell membrane. Smaller peptides such as the 
TNL, TNLY, and TNLYM moiety exhibited no binding at concentrations of up to 200 
M, despite T1, L3 and M5 providing extensive hydrophobic binding contacts to LpxA 
in the parent peptide. These data suggests that truncating the consensus sequence 
(YMLP) observed across the RJPXD33 series of peptides is detrimental to binding. 
However these results may also be explained by an increase in conformational flexibility 
of the truncated peptides. If this hypothesis is correct, restricted peptides could be 
synthesized which may display increased potency and bioavailability. One could envision 
substitutions at the N2 and Y4 residues to allow covalent cyclization, as these two 
residues appear to form an amide- interaction. However, the hydrophobic nature of the 
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Y4 residue may provide energetically favorable binding within the hydrophobic cleft and 
thus linking strategies including a phenyl ring may need to be pursued. 
It remains unclear as to how RJPXD33 interacts with E. coli LpxD. In order to 
shed light on this interaction, EcLpxD (PDB 3EH0) was superimposed on the structure of 
Chlamydia trachomatis LpxD (PDB 2IU8) with bound UDP-GlcNAc and palmitate 
(Figure 4.7A) to highlight the similar binding domains between the two proteins (34,35). 
A hypothetical binding model of the RJPXD33•LpxD was next proposed using a 
structural overlay between the RJPXD33•EcLpxA complex and EcLpxD (Figure 4.7B).  
From these overlays, it is predicted that RJPXD33 would occupy a similar fatty acyl 
binding groove in EcLpxD as compared to the palmitate in the CtLpxD structure. The six 
C-terminal residues of RJPXD33 would potentially extend into a binding groove near the 
C-terminal -helical domain of EcLpxD. This would explain the role of the six C-
terminal residues with respect to the increased affinity for LpxD when compared to 
LpxA. RJPXD33 does not occupy the UDP-GlcNAc binding domain in this model 
suggesting that more potent analogues may be accessed through the addition of moieties 
that allow for favorable binding interactions within this region. 
The RJPXD33•LpxD complex was unable to be crystallized, prompting other 
routes to be pursued to validate this binding model. Photo-activatable amino acids have 
been used to map protein•protein and protein•peptide interactions, offering an alternative 
to crystallization (15,36). MS analysis should provide insights into the region where the 
peptide is interacting with LpxD. Furthermore, high resolution MS/MS may allow for the 
identification of the exact amino acid residue to which the photo-affinity derivative is 
cross-linked to.  These data should provide enough evidence to validate the existing 
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molecular model or formulate a new model from which more potent analogues can be 
generated with the future goal of developing peptidomimetics compounds that are cell 
permeable. This model may also provide insights into how acyl-PPan of ACP binds to 
LpxD, providing a structural basis for the catalytic mechanism of this acyltransferase. 
 
Figure 4.7. Hypothetical binding model of the RJPXD33•LpxD complex. A. Overlay of E. coli LpxD 
(wheat; PDB 3EH0) and C. trachomatis LpxD (yellow; PDB 2IU8). The palmitate and UDP-GlcNAc 
residues were co-crystallized with CtLpxD, highlighting their binding domains in comparison to the 
EcLpxD structure. B. The EcLpxA•RJPXD33 complex was superimposed onto EcLpxD (wheat; PDB 
3EH0). RJPXD33 (magenta) would occupy the fatty acyl binding groove between two monomers in 
EcLpxD, similar to palmitate in CtLpxD. The six c-temrinal amino acids of RJPXD33 would potentially 
extend into a binding groove near the C-terminal -helical extension of EcLpxD. This model predicts that 
RJPXD33 does not extend into the UDP-GlcNAc binding domain offering a way to potentially increase 
potency with future analogues. 
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Cell Permeable Inhibitors of E. coli UDP-3-O-(R-3-hydroxyacyl)-glucosamine N-
Acyltransferase (LpxD)  
Introduction 
 Acyl carrier protein (ACP) is a key component for fatty acid synthesis (FAS) in 
all kingdoms of life (1). ACP is post-translationally modified on a conserved serine 
residue with a 4’-phosphopantehtiene moiety, derived from coenzyme A (CoA) (2). 
Mammals utilize a type I FAS system in which each catalytic domain is encoded on a 
single polypeptide chain (3). The mammalian FAS machinery primarily elongates the 
acyl chain to a length of 16 – 18 carbons and then cleaves the thioester between the acyl 
chain and phosphopantetheine arm to release free fatty acids into the cytosol (4). The free 
fatty acids can be activated onto CoA and subsequently used as acyl donors for a variety 
of enzymatic reactions and regulatory functions (5) In contrast, Escherichia coli, and 
most other prokaryotes, contain a type II FAS pathway, where each functionality required 
for FAS is encoded on its own polypeptide chain (6). Type II ACP, and its various 
acylated analogs, are small soluble proteins which serve a pivotal role as substrates for 
the biosynthesis of a large number of vital/essential bacterial molecules, including fatty 
acids, phospholipids, lipopolysaccharide, lipoic acid, and acyl homoserine lactones (7-
10). As such ACP must interact with a vast number of functionally different enzymes. 
The requirement for ACP in these diverse processes suggests that interactions between 
ACP and ACP-dependent enzymes must be specific.  However, the transient nature of the 
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specific protein•protein interface between ACP and its many interactive proteins has not 
been delineated in most instances. 
 Peptidic inhibitors that have been identified against both LpxD and LpxA suggest 
that small molecule inhibitors could be identified that disrupt the protein•protein 
interaction between early acyltransferases involved in lipid A biosynthesis and acyl-ACP 
(11,12). While inhibition of protein•protein interactions in mammalian cells has been 
widely appreciated as an innovative chemotherapeutic approach (13,14), it represents an 
underexplored niche in the field of antimicrobial drug discovery. The ability for bacterial 
ACP to interact with a diverse array of essential proteins, offers the possibility that dual 
targeting inhibitors of ACP-dependent enzymes could be identified (15). Such dual 
targeting inhibitors would decrease the likelihood of mutation-mediated resistance by 
increasing the minimal number of gene mutations necessary to confer resistance to the 
microbe (16). 
 Previously, an LpxA/D fluorescence polarization (FP) binding assay and a 
continuous, fluorescence-based LpxA/D activity assay were developed (12,17). 
Described within, the FP binding assay was adapted to a 384-well format and utilized to 
screen ~120,000 small molecules. Compounds which disrupted the FITC-
RJPXD33•LpxD interaction in the primary screen were tested for inhibition using the 
secondary fluorescent acyltransferase assay. Inhibitory molecules that were confirmed to 
target LpxD in vitro were subsequently tested for growth inhibition in multi-drug efflux 
pump deficient (tolC) E. coli. This led to the identification of several cell permeable 
inhibitors with antimicrobial activity. A multi-copy suppressor approach was used to 
validate that inhibition of LpxD was the molecular mode of action for E. coli growth 
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inhibition. These molecules represent the first cell permeable inhibitors of LpxD 
identified to date, offering a significant first step towards future development of LpxD 
inhibitors for chemotherapeutic application. 
Materials and Methods 
Materials. Bio-Rad Protein assay and BioGel P2 size exclusion gel were 
purchased from Bio-Rad. LB (Lenox) broth and agar were purchased from Difco. 
Fluorescein isothiocyanate (FITC) was purchased from Acros Organics. ThioGlo1 was 
purchased from CalBioChem. Benzonase was purchased from Novagen. R-3-
hydroxymyristic acid was purchased from Wako Chemicals. All buffers and antibiotics 
were purchased in the highest grade from Sigma Aldrich or Fisher. Inhibitor compounds 
were purchased from ChemDiv. MC207110 (Phe-Arg -naphthylamide dihydrochloride) 
was purchased from Sigma Aldrich. A PheraStar spectrophotometer was used for the 
high-throughput screening of LpxD. A SpectraMax M5 spectrophotometer was used for 
all other experiments. E. coli strain JW5503-1 (18) was provided by the Yale E. coli 
Genetic Stock Center. 
Cell Culture. Bacteria strains and plasmids have been described previously (17). 
For protein expression and purification, all E. coli/T7 RNA polymerase promoter 
constructs were grown in 1 L baffled flasks containing 250 mL LB media supplemented 
with the appropriate antibiotics. The Flasks were shaken (250 rpm) at 37 °C until the 
cells reached an optical density of OD600 = 0.6 -1.0. The cultures were then induced with 
1 mM isopropyl -D-1-thiogalactopyranoside (IPTG) (Rosetta (DE3/pLysS)) or 1 mM 
IPTG and 0.2% L-arabinose (BL21-AI), and the cultures were allowed to incubate at 37 
°C for an additional 4 h. Cells were harvested at 4 °C by centrifugation at 6,000 x g and 
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lysed by French press. Crude cytosol was prepared by centrifugation of cellular lysate at 
20,000 x g for 30 min at 4 °C. 
Overexpression and Purification of His6-LpxD. Overexpression and purification 
of His6-LpxD were carried out as previously described (17). For His6-LpxD purification, 
Benzonase (Novagen) was added after cell lysis and the lysate was incubated for 30 min 
on ice prior to cytosol preparation. Ten milliliters of crude cytosol in 20 mM HEPES, 50 
mM imidazole pH 8.0 was loaded onto 3 mL of Ni-NTA resin (Qiagen) equilibrated in 
loading buffer.  The resin was washed with 10 column volumes of loading buffer 
containing 500 mM NaCl and then eluted with 20 mM HEPES, 250 mM imidazole pH 
8.0.  Purified His6-LpxD was desalted on a Bio-Gel P2 column and analyzed by SDS-





 for LpxD. 
Purification of Other Enzymes and Preparation of Substrates. Overexpression and 
purification of LpxA, ACP, LpxC, and AasS, acylation of ACP and preparation of UDP-
3-O-(R-3-hydroxymyristoryl)-GlcN have been described previously (17). 
High-Throughput Screening (HTS) Assay. HTS was carried out using the 
fluorescence polarization (FP) binding assay for LpxD (12). For initial screening, 
compounds were spotted on to 384-well, black plates (Costar) at a final concentration of 
100 M in 1 % DMSO. The final assay volume was 20 L and contained 600 nM LpxD 
and 20 nM FITC-RJPXD33. Individual compounds were incubated with LpxD for 10 
min prior to addition of FITC-RJPXD33 and plates were subsequently read on a 
PheraStar spectrophotometer, ex = 485 nm and em = 525 nm.  
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Acyltransferase Inhibition Assay. The acyltransferase reaction was monitored in 
the forward direction using a continuous fluorescent assay as previously described (17). 
The assay monitors holo-ACP formation via conjugation to ThioGlo1 reagent, which 
could be monitored as an increase in fluorescence with excitation and emission 
wavelengths set to ex = 379 nm and em = 513 nm. Assays were performed on a 
SpectraMax M5 microplate reader (auto cutoff set to  = 495 nm, PMT set to low, and 
precesion set to 40 scans per well) using Corning black, 96-well half area plates. The 
assay mixture in a final volume of 100 L contained 20 mM HEPES pH 7.5, 10 M 
ThioGlo, 4.5 M UDP-3-O-(R-3-hydroxymyristoyl)-GlcN, 9 M R-3-hydroxymyristoyl-
ACP, 10 nM LpxD and varying concentrations of inhibitors (1 – 100 M). Assays 
contained a final concentration of 2% (v/v) DMSO from stock solutions. All components 
with the exception of enzyme were mixed and incubated in the dark at 30 °C for 5 min. 
To initiate the reaction, a fresh dilution of acyltransferase from a 1 mg/mL stock was 
added and the reaction was monitored for 10 min using the linear range (< 10% product 
formation) for initial velocities. Assays were run in triplicate with the average IC50 being 
reported. A negative control containing no inhibitor and a positive control containing no 
acyltransferase were used for 100% and 0% relative activity. IC50‘s were determined by 







   




Where vi is the initial velocity in the presence of inhibitor, vo is the initial velocity in the 
absence of inhibitor, [I] is the concentration of inhibitor, IC50 is the concentration of 
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inhibitor at 50% inhibition, and h is the hill slope. Data points shown represent the mean 
of three individual experiments and error bars represent the standard deviation. 
Disk Diffusion Assay. A single colony of bacteria was selected and grown 
overnight at 37 °C in 5 mL of LB media. Overnight cultures were diluted to an OD600 = 
0.2 in a final volume of 1 mL LB media. With a sterile cotton swab, the diluted culture 
was streaked out to completely cover an LB agar plate. The plate was allowed to dry at 
room temperature for 10 min. Compounds were added directly to a sterile filter disc from 
a 25 mM stock solution in DMSO. Filter discs containing compounds or controls were 
placed onto the dried plates and incubated at 37 °C overnight for a minimum of 20 h. 
Diameters were measured the following day. Any compound lacking a ring beyond the 
filter disc was annotated as <6 mm diameter. DMSO was plated as a negative control and 
displayed no inhibition up to 33 mg (30 L; highest amount tested). Chloramphenicol 
was used as a positive control at 10 g for each plate. 
 Determination of Minimal Inhibitory Concentration (MIC). A single colony of 
JW5503-1 with pUC18 or pUC18::lpxD was selected and grown at 37 °C in 5 mL of LB 
with 30 g/mL kanamycin until an OD600 = 0.6-0.8 was reached. The culture was diluted 
to an OD600 = 0.04. 50 L of the diluted culture was then added to 50 L of two-fold 
serially diluted compound (final concentrations 0.003 – 100 g/mL) in LB media in a 96-
well, half-area, clear plate (Costar UV). The plate was covered and the cells were grown 
at 37 °C for 20 h at which point an OD600 was measured. MIC’s were defined by the 
minimal concentration at which the bacteria did not grow. All MIC’s were determined in 
quadruplicate and the error was within one serial dilution of the MIC. For statistical 
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analysis of compound 6359-0284 in JW5503-1::pUC18 and JW5503-1::pUC18-lpxD, the 
MIC’s obtained for all four experiments were compared using a two tailed paired t-test. 
 Checkerboard Synergy Analysis. A six by six dose dependence checkerboard 
assay was set up as described by Orhan et. al (19). Cultures were set up exactly as 
described under MIC determinations using JW5503-1 lacking any plasmids. Fractional 
inhibitory concentrations (FIC) were calculated using the following equation: 
    (
    
    
)  (
    
    
) 
Where MICA = MIC of compound A, MICB = MIC of compound B, FICA = fractional 
inhibitory concentration of compound A and FICB = fractional inhibitory concentration of 
compound B. FIC were defined as antagonistic if FIC > 4, additive if 4 > FIC > 0.5, and 
synergistic if FIC < 0.5. 
Synthesis of 1-(2-methoxyphenyl)-3-(naphthalen-2-yl)urea (INF271). Synthesis 
was carried out as previously described (20). A solution of 2-methoxyphenyl isocyante 
(298 mg, 2 mmol) was prepared in 2 mL of diethyl ether and added drop wise to a slurry 
of 2-napthylamine (286 mg, 2  mmol) in 2 mL of diethyl ether. The solution was stirred 
for 2 h at room temperature. Upon addition of the 2-methoxyphenyl isocyanate, the 2-
napthylamine began to dissolve. Within 30 min a white precipitate formed. After 1 h, 2 
mL of ether was added to the round bottom due to the exothermic reaction causing ether 
evaporation. After two hours there was a complete loss of starting material as monitored 
by TLC. The precipitate was filtered and washed three times with 15 mL of diethyl ether 
resulting in a 63% isolated yield. The compound is very hygroscopic and ~95% pure by 
analytical HPLC (see Appendix). 
1
H NMR (400 MHz, CDCl3) d 8.14 (dd, J = 7.7, 1.8, 
1H), 7.94 (d, J = 1.9, 1H), 7.75 (dd, J = 11.6, 8.6, 3H), 7.47 - 7.35 (m, 4H), 7.06 - 6.94 
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(m, 3H), 6.87 (dd, J = 7.8, 1.5, 1H), 3.80 (s, 3H). ESI-HRMS calculated for C18H16N2O2 
[M+Na]
+
 315.1104, 315.1115 observed. 
Results 
 LpxD was screened using a 384-well fluorescence binding assay previously 
reported (12). The FP binding assay was optimized to 20 L final volume to allow for an 
increase with respect to final inhibitor concentration and a decrease in the amounts of 
total protein (LpxD). From initial experiments, the Z-factor was shown to be 0.84 (Figure 
5.1), with an average Z-factor per plate of 0.79, indicating an excellent assay for high-
throughput screening (HTS) according to Zhang et. al. (21). Approximately 120,000 
compounds were screened for disruption of the FITC-RJPXD33•LpxD complex. Active 
hits were defined as displaying inhibition greater than or equal to three standard 
deviations above the negative control. Compounds known to exhibit intrinsic 
fluorescence, promiscuity in prior HTS efforts against various protein targets and those 
containing chemically reactive structural groups were triaged from the active hits. A 
second round of screening was conducted in triplicate against ~1600 of the primary 
actives. In this follow up screen individual compounds were first assessed for intrinsic 
fluorescence, followed by fluorescence quenching upon addition of FITC-RJPXD33. 
Compounds were then assayed for re-confirmation of disruption of FITC-RJPXD33 
binding to LpxD. Of the nearly 1600 compounds, 462 were confirmed and chosen for 
dose response evaluation in which several concentrations (1-100 M) of each compound 
was evaluated in the LpxD FP binding assay. Additionally, these same 462 compounds 
were subsequently screened against LpxA using an FP binding assay with FITC-P920 to 




Figure 5.1. Z-score determination for the LpxD FP assay. Negative controls contain 20 nM FITC-
RJPXD33 and 600 nM LpxD. Positive controls contain only FITC-RJPXD33. A Z-score of > 0.75 indicates 
a very good assay. 
 
 Fourteen compounds were chosen for in vitro evaluation using the acyltransferase 
activity assay based on their potency (pAC50; > 3 standard deviations from the negative 
control), lack of promiscuity (< 10% hit rate) and hill slope (< 3) from the dose-response 
curves. Promiscuity and high hill slopes are indicative of aggregation-based inhibitors 
which are pitfalls in HTS (23,24). Of the fourteen compounds chosen, only two were 
inactive (one demonstrated intrinsic fluorescence which would interfere with the assay 
and a second was extremely insoluble). Eleven compounds (Figure 5.2) exhibited IC50s 
ranging from low nanomolar to low micromolar (0.07 – 35 M). Acyltransferase activity 
inhibition plots of the HTS hits are shown indicating the IC50 in micromolar and the Hill 
slope from the dose response of three individual assays (Figure 5.3, panel a – k). All 
compounds exhibited hill slopes between 0.6 and 1.4 reconfirming that these were viable 




Figure 5.2. Compounds identified from the LpxD HTS that were tested in the acyltransferase assay. 

























































Figure 5.3k. Acyltransferase inhibition plot of E. coli LpxD vs C200-4634. 
 
 All compounds were tested for bioactivity using a disc diffusion assay to 
determine growth inhibition an E. coli MG1655 mutant (JW5503-1) (18). This strain is 
lacking the multi-drug efflux transport system (tolC) which contains a kanamycin 
cassette in place of tolC. Three of the fourteen compounds demonstrated the ability to 
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inhibit growth of the tolC mutant (Figure 5.4 & Table 5.1). Figure 5.3 represents a 
single plate, though compounds were tested in triplicate and similar data were obtained 
for each plate. Compounds C200-4634 and 6359-0289 demonstrated modest to high 
growth inhibition (10 – 20 mm diameter) at 300 g. However, compound 6359-0284 at 
25 g demonstrated growth inhibition comparable to 10 g of either ampicillin (Amp) or 
chloramphenicol (Cam).  
 
Figure 5.4. Representative disc diffusion assay for 6359-0284 & 6359-0289 against JW5503-1 in 
comparison to commonly used antibacterial inhibitors. Inhibition rings were measured for 1) 6359-0284 
(25 g), 2) 6359-0289 (300 g), 3) Ampicillin (10 g), 4) Chloramphenicol (10 g) and 5) DMSO (33 mg; 
highest amount of DMSO used). Inhibition diameters are shown in Table 5.1. Plates were run in triplicate. 
 
 
Compound Amount (g) Diameter (mm) 
6359-0284 25 25 
Ampicilin 10 22 
Chloramphenicol 10 28 
6359-0289 300 21 
6359-0289 25 8 
C200-4634 300 10 





 Compounds 6359-0284 and 6359-0289 bearing a common molecular 
substructure, were further tested for minimal inhibitory concentration (MIC) in liquid 
growth medium. 6359-0284 demonstrated an MIC = 3.13 g/mL against JW5503-1, 
while 6359-0289 demonstrated an MIC = 100 g/mL. This correlated well with our 
enzyme inhibition results, as 6359-0284 displayed 10-fold higher inhibition (IC50 = 3.2 + 
0.7 M) for LpxD than 6359-0289 (IC50 = 30.5 + 4 M).  
In order to determine whether JW5503-1 growth inhibition was dependent on 
LpxD, a multi-copy suppression experiment was performed. JW5503-1 was transformed 
with an empty pUC18 vector (JW5503-1::pUC18) or a pUC18 vector carrying the lpxD 
gene (JW5503-1::lpxD). These two strains were then tested against 6359-0284 and a 
variety of known antibiotics which target different cellular processes. Rifampin inhibits 
RNA transcription, Nalidixic Acid targets DNA synthesis, Chloramphenicol blocks 
protein synthesis, Triclosan inhibits FAS, Fosfomycin inhibits early steps of 
peptidoglycan biosynthesis within the cytoplasm and Cefixime is a third generation 
cephalosporin (inhibits peptidoglycan cross-linking in the periplasm) which is resistant to 
hydrolysis by many -lactamases, such as the one carried by the pUC18 plasmid. As 
observed in Table 5.2, only compound 6359-0284 was susceptible to overexpression of 
LpxD. Rifampin is one of many hydrophobic antibiotics that have been shown to be more 
potent against LPS-deficient mutants, owing to the inherent permeability barrier imparted 
by LPS (25,26). Overexpression of LpxD had no effect on the potency of Rifampin, 
suggesting that overexpression of LpxD was not simply increasing LPS production and 
causing a decrease in bioavailability of the antimicrobials. This would ultimately suggest 
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that 6359-0284 was directly inhibiting LpxD as seen by the suppression of toxicity only 
with this compound. 
MIC (g/mL) 
Compound JW5503-1::pUC18 JW5503-1::lpxD Fold Difference 
6359-0284 3.13 100 32 
Rifampin 6.25 6.25 1 
Nalidixic Acid 0.78 1.56 2 
Chloramphenicol 1.56 1.56 1 
Triclosan 0.002 0.001 0.5 
Fosfomycin 12.5 12.5 1 
Cefixime 3.13 6.25 2 
Table 5.2. MIC data for JW5503-1::pUC18 and JW5503-1::lpxD. MIC’s are representative of four 
individual experiments. Errors of the MIC’s are within a 2-fold dilution of the defined value. 
 
While 6359-0284 demonstrated toxicity in multi-drug efflux deficient E. coli, no 
activity was seen in wild-type E. coli MG1655. From the above results, we hypothesized 
that TolC inhibitors could potentially be used in combination with 6359-0284 to inhibit 
the growth of MG1655. Compound MC207110 was identified against the Pseudomonas 
aeruginosa MexAB-OmpR multi-drug efflux system and has shown broad spectrum 
applicability (27,28). MC207110 has been used in combination with a TolC inhibitor, 
INF271, for increased potency of antimicrobials that are substrates for efflux pumps (28). 
MC207110 was commercially available and compound INF271 was synthesized in a single 
step from napthylamine and 2-methoxyphenyl isocyanate (Figure 5.5) (20,27,28). In the 
presence of 20 g/mL of MC207110, compound 6359-0284 displayed an MIC = 50 g/mL. 
While the MIC of 6359-0284 was > 100 g/mL in combination with 10 g/mL of INF271, 
when both 10 g/mL of INF271 and 20 g/mL of MC207110 were utilized in combination 
with 6359-0284, the MIC was observed to be 25 g/mL. As a control, MC207110 and 
INF271 were tested for growth inhibition aginst E. coli MG1655 and did not inhibit 
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growth at concentrations up to 5 times the concentration utilized with 6359-0284. 
MC207110 did not inhibit growth at concentrations up to 200 g/mL, while INF271 
displayed no inhibition up to 50 g/mL. These results in combination with the tolC 
mutant highlight that 6359-0284 is the first cell permeable inhibitor of LpxD. 
 
Figure 5.5. Multi-drug efflux pump inhibitors, INF271 and MC207110. 
 
One of our initial hypotheses was that inhibitors of LpxD would demonstrate a 
synergistic increase in potency when combined with other antibacterial compounds. This 
hypothesis stemmed from the fact that mutants deficient in LPS have demonstrated 
increased potency to clinically relevant antimicrobials (25,26,29,30). To test whether 
LpxD inhibitors would demonstrate synergy in potency with other antibiotics, a 
checkerboard synergy analysis (Figure 5.6) was performed on JW5503-1 utilizing 6359-
0284 in combination with a variety of commercially available antibiotics Table 5.3 (19). 
Multiple compounds demonstrated a synergistic increase in potency in combination with 
6359-0284, including the hydrophobic antimicrobial, Rifampin (RNA synthesis 
inhibitor). Despite the hydrophobicity of Triclosan (ClogP = 5.53), it only demonstrated 
an additive effect. While this may be surprising, our analysis represents the first synergy 
experiments using Triclosan in combination with chemical or genomic disruption of lipid 
A biosynthesis. The synergistic effect seen in combination with Nalidixic acid and 
Chloramphenicol are in agreement with an increased potency of DNA gyrase inhibitors 
108 
 
(Novobiocin) and protein synthesis inhibitors (Chloramphenicol) in lipid A defective 
mutants (25). Previous studies have shown conflicting effects (an increase or no increase 
in potency) on lipid A deficient mutants using various cephalosporins (25), and Cefixime 
did not show synergism with 6359-0284. Interestingly, 6359-0284 demonstrated the 
highest synergy with Fosfomycin, despite only an additive effect with a peptidoglycan 
cross-linking inhibitor (Cefixime). 
  1 2 3 4 5 6 7 8 9 10 11 12 
A Pos Pos Pos Pos Pos Pos Pos Pos x x x x 
B Neg Neg Neg Neg Neg Neg Neg Neg x x x x 
C 2x 2.13 2.25 2.5 3 4 2x 2.13 2.25 2.5 3 4 
D 1x 1.13 1.25 1.5 2 3 1x 1.13 1.25 1.5 2 3 
E 1/2x 0.63 0.75 1 1.5 2.5 1/2x 0.63 0.75 1 1.5 2.5 
F 1/4x 0.38 0.5 0.75 1.25 2.25 1/4x 0.38 0.5 0.75 1.25 2.25 
G 1/8x 0.25 0.38 0.63 1.13 2.13 1/8x 0.25 0.38 0.63 1.13 2.13 
H 0 1/8x 1/4x 1/2x 1x 2x 0 1/8x 1/4x 1/2x 1x 2x 
Figure 5.6. Checkerboard synergy analysis experimental set up in a 96-well plate. Compound 6359-0284 
was titrated along the ordinate of a 96 well plate at concentrations of 2x MIC, 1x MIC, 1/2x MIC, 1/4x 
MIC, and 1/8x MIC (yellow). Other antimicrobials were titrated along the abscissa at varying 
concentrations from 2x to 1/8x MIC (yellow). FIC’s of individual wells are denoted in blue and calculated 
as described in the Materials and Methods. The well with the lowest FIC displaying no growth determined 
the FIC. Positive controls (green) contained only LB media lacking JW5503-1, while negative controls 
(red) contained LB media and JW5503-1 without any compounds. X’s mark wells that were not utilized in 
the experiments. 
 
Synergy Analysis with 6359-0284 
Compound FIC Activity 
Rifampin 0.38 Synergy 
Triclosan 0.75 Additive 
Nalidixic Acid 0.38 Synergy 
Chloramphenicol 0.38 Synergy 
Cefixime 0.75 Additive 
Fosfomycin 0.25 Synergy 
Table 5.3. Synergy analysis data using compound 6359-0284. 
Discussion 
Utilizing our previously described assays as a toolbox, we have discovered and 
validated the first cell permeable inhibitors of LpxD. Through a multi-copy suppressor 
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approach and growth inhibition of tolC knockouts, we validated that the intracellular 
target was LpxD. Furthermore, additional synergy data confirmed our initial hypothesis 
that such compounds could find use in combination therapies with existing antimicrobials 
to cause a synergistic increase in potency of these compounds. One of the large questions 
still remaining is the fundamental understanding of how these inhibitors bind to LpxD. 
This information will be critical in the design of more potent and bioavailable analogs. 
Structural work complemented with structure-activity relationship (SAR) should assist in 
answering this important question. 
The most potent compound, G284-0533 (IC50 = 72 nM), displayed structural 
similarity to compounds 3031-0919, C672-0030 and G682-0070 (Figure 5.2). All 
compounds contained a phenyl dioxane or phenyl dioxolane ring system followed by an 
amide linkage leading to a heteroaromatic ring system. The heteroaromatic ring system is 
where all compounds differ, perhaps leading to the variation in affinity (0.72 – 20.7 M). 
While C200-4634 does not contain a phenyl dioxane ring, the 4-amino-5-tosyl motif 
connected to the triazole ring is highly similar to the 1,2,3-Benzothiadiazine heterocyclic 
ring in compound G682-0070. The fact that C200-4634 was cell permeable and 
approximately 3 times more potent than G682-0070 raises the question of whether 
synthesizing only the heteroaromatic ring system of the dioxane series would provide 
potent cell permeable inhibitors of LpxD. The heteroaromatic ring system may be 
mimicking the uridine ring of UDP-3-O-(R-3-hydroxyacyl)-GlcN, which may allow for 
additional hydrophobic groups to be placed off of the ring to mimic the fatty acyl chain. 
However, this is simply one hypothesis and a fundamental understanding of how these 
compounds binds is necessary before drawing such conclusions. 
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The most potent biologically active compounds contained a pyrazolo-quinolone 
scaffold. Other compounds containing the pyrazolo-quinolone scaffold similar to 6359-
0284 and 6359-0289 were also found within the screening library, but were not tested in 
the continuous enzyme assay. From the HTS binding data, the gem dimethyl moiety off 
of the C7 of the quinolone ring was not necessary for binding, but did increase binding 
affinity (Figure 5.7). Substitutions to or deletion of the 3-hydroxyl of the pyrazole ring 
were not tolerated as this aided in constraining the aryl ring off of the C4 of the quinolone 
ring. Only six membered aryl rings substituted at the C2 position (X) or five-membered 
heterocyclic aryl rings with a heteroatom at the second position (Y) were tolerated, 
further highlighting the necessity to constrain the aryl ring system. The stereochemistry at 
the C4 position was racemic and the chlorine substitution of the aryl ring may adopt an 
exo or endo geometry, further complicating the mechanism of binding.  
Substitutions at the phenyl moiety of the pyrazole ring can be achieved using an 
aryl hydrazine and ethyl cyanoacetate (31). The newly synthesized aryl pyrazole ring can 
be added to a one-pot reaction with an aryl aldehyde and a 1,3-cyclohexanedione 
derivative for the one step synthesis of novel pyrazolo-quinolone compounds (32). SAR 
around the aryl aldehyde, the aryl pyrazole, and the 1,3-cyclohexanedione may identify 
compounds with increased potency that are not substrates for TolC. 
 
Figure 5.7. Pyrazolo-Quinolone structure. Substitutions at position X or off the phenyl moiety of the 





The synergy seen between 6359-0284 and Fosfomycin (a phosphonate-based 
antimicrobial) suggested that decrease in lipid A content may increase the bioavailability 
of Fosfomycin. This possibility is interesting since normally Fosfomycin must be actively 
transported into the cell via the glycerol phosphate transporter (33). Lipid A inhibitors 
may open a window of opportunity for the use of phosphate-based chemotherapeutics 
which would otherwise have little chance of traversing the outer cell membrane without 
some sort of active transport mechanism (34). Thus, further synergy experimentation 
with phosphate containing compounds should be conducted in combination with 6359-
0284, as well as with other inhibitors of lipid A biosynthesis. 
An alternative hypothesis for the synergy may be caused by an increase of toxic 
lipid A intermediates beyond the first committed step (LpxC). Fosfomycin is a natural 
product inhibitor of MurA (33,35), the first step in peptidoglycan biosynthesis (Figure 
5.8). Inhibition of MurA would result in the build-up of UDP-GlcNAc, the common 
precursor for lipid A and peptidoglycan, which may be shunted towards lipid A 
biosynthesis. Since LpxD is beyond the first committed step, inhibition of this enzyme 
would sequester intermediates derived from UDP-GlcNAc, and accumulate detergent-
like compounds (UDP-3-O-(R-3-hydroxyacyl)-GlcN) that are hypothesized to be toxic to 
the microbe. This scenario also raises questions of if, and how the processes of 
peptidoglycan biosynthesis and lipid A are regulated with regards to one another? Ogura 
et. al. displayed that the FtsH protease regulates LpxC with regards to fatty acid 
biosynthesis and phospholipid biosynthesis (36), but similar questions regarding 




Figure 5.8. Lipid A and peptidoglycan biosynthesis. Both lipid A and peptidoglycan are synthesized from 
the precursor UDP-GlcNAc. Fosfomycin (red) inhibits the first step of peptidoglycan biosynthesis, whereas 
6359-0284 (red) inhibits the third step of lipid A biosynthesis. LpxD is beyond the first committed step 
(LpxC) and may sequester UDP-GlcNAc away from peptidoglycan.  
 
Our observations warrant further research and exploration with regards to the 
regulation between the peptidoglycan and lipid A biosynthetic pathways. While 
temperature sensitive mutants have been a boon in identifying the genes within the lipid 
A pathway, they require a global physiological change to decrease the quantities of lipid 
A (37-40). The membrane stress response is intimately tied to the heat shock response, 
and thus increasing temperature could adversely affect the integrity of these experiments 
(41,42). These inhibitors could be utilized to address the effects on peptidoglycan when 
lipid A biosynthesis is decreased, without a global physiological change. In combination 
with LpxC inhibitors, this question could further be elaborated on to explore how 
peptidoglycan is affected when lipid A is inhibited before and after the first committed 
step. This would be an important experiment as inhibition of LpxC may alter the flux of 
UDP-GlcNAc towards the peptidoglycan biosynthetic pathway, whereas 6359-0284 may 
alter the flux away from peptidoglycan biosynthesis. 
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The inhibitors discovered in this study should allow for a fundamental 
understanding of whether UDP-3-O-(R-3-hydroxyacyl)-GlcN associates with the inner 
membrane at high concentrations. It has been previously shown that inner and outer 
membrane ratios of lipid A are altered with lipid A lacking all secondary acyl chains (43). 
These mutants can grow below 32 °C, but have a drastic increase in the ratio of lipid A to 
phospholipids in the inner membrane. However, it is poorly understood how lipid A 
precursors affect inner membrane protein folding and activity. Inhibitors of early lipid A 
biosynthesis could be utilized in conjunction with these mutants to probe the effect of the 
accumulation of lipid A intermediates on inner membrane proteins. In vitro studies on the 
function of E. coli membrane proteins reconstituted in lipid nanodiscs supports the notion 
that catalytic activity is heavily dependent on the type of lipid introduced into the disc 
(44,45). Therefore, studying the accumulation of these intermediates may provide novel 
insights into both protein structure and function, as well as how microbes regulate 
membrane homeostasis through activation or deactivation of various membrane proteins 
under different lipid conditions. Thus, while our inhibitors will find utilization towards 
future medicinal chemistry efforts, they may also be used to answer intriguing biological 
questions. 
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Conclusion & Future Directions 
Conclusion 
 My thesis work has encompassed the development of novel tools to study the 
lipid A biosynthetic pathway, along with the identification and molecular characterization 
of inhibitory probes targeting this pathway. Prior to our work, Raetz and co-workers had 
identified the first inhibitor of lipid A biosynthesis that targeted LpxC (1). With the 
exception of the identification of the E. coli LpxA selective peptide 920 (2,3), much 
focus in the field has involved the optimization of LpxC inhibitors (4-8). Most of the 
pathway has been largely ignored due to the lack of chemical and biological tools to 
probe the pathway for inhibitors.  
In order to remedy the lack of tools to study lipid A biosynthesis, we developed a 
continuous enzyme assay that could monitor the turnover of LpxA and LpxD. While 
developing the enzyme assay, we had identified an inhibitory peptide, RJPXD33, that 
was found to target both LpxD and LpxA. Such dual targeting inhibitors offer the 
advantage of decreasing the likelihood of mutation-mediated resistance by necessitating 
mutations in more than one essential gene (9,10). In the same study, RJPXD33 and P920 
were turned into chemical probes by linking a fluorescent marker on the peptides and 
performing fluorescence polarization (FP). This assay was more advantageous for use in 
high-throughput screening (HTS) efforts in comparison to the 
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continuous enzyme assay, as it does not require large quantities of the LpxD substrates, 
which are difficult to obtain. 
 We performed structural and biochemical studies to fundamentally understand 
how RJPXD33 is able to bind and inhibit both LpxA and LpxD. From the co-crystal 
structure of RJPXD33•LpxA and biochemical validation, we identified the minimal motif 
–TNLYML– that was required for binding to LpxA. While development of 
peptidomimetics from twelve amino acids may prove to be difficult, truncation to six 
amino acids provides an excellent starting point for the design and development of more 
potent small molecule analogues with increased bioavailability. Though we were unable 
to crystallize LpxD bound to RJPXD33, we utilized a photo-crosslinking strategy (11) to 
identify where RJPXD33 was binding to LpxD. 
 Using our newly developed tools, we were able to screen a large library of 
chemical compounds for disruption of the FITC-RJPXD33-LpxD complex. This assay 
allowed for rapid screening (~120,000 compounds in 5-6 days) and provided the first 
small molecule inhibitors of LpxD. Inhibitors were validated using the continuous 
enzyme assay and further tested for in vivo inhibition in tolC deficient E. coli. Through 
an LpxD multi-copy suppressor approach, we provided support that the intracellular 
target of these inhibitors was LpxD. Synergy analysis provided evidence that these 
inhibitors could further be utilized in combination with existing antimicrobials to provide 
a synergistic increase in potency. 
Future Directions 
 A methodology which allows for rapid and large-scale synthesis of the substrates 
of the early enzymes of lipid A is needed. While the LpxC substrate can be purchased at 
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$1000/mg, this is not plausible for many academic labs. Our attempts to produce an ACP 
recycling system produced only limited success. The temperature sensitive mutants of 
LpxC, LpxD and LpxH offer an avenue for large scale purification (12-14). Such efforts 
have been successful in producing lipid X in 0.1 – 1 g quantities (15). However, all 
substrates up until lipid X contain a UDP moiety which complicates the purification. An 
alternative approach to the LpxD substrate would entail chemical synthesis of the LpxC 
substrate, followed by enzymatic deacetylation. An existing synthesis exists, but relies on 
separation of diastereomers upon phosphorylation of the protected glucosamine ring (16). 
Much effort has been placed on developing phosphorylation and sugar chemistry since 
the initial publication (17,18). Our lab has confirmed that the phosphorylation of the 
anomeric hydroxyl of GlcNAc can be performed stereospecifically. However, the 
synthesis would still be ardous with more than seven steps and a final UMP 
morpholidation reaction which are generally low yielding. Thus both directions should be 
pursued in order produce a reliable method that can be scaled up. 
 Future work with design of peptidomimetics targeting LpxA will revolve around 
identifying the amino acids which contribute the highest binding affinity to LpxD/LpxA. 
A simple alanine scan can be performed with FITC-labeled mutants (19). Subsequent 
mutations of residues with unnatural amino acids should provide valuable information 
with regards to potency. A second approach should aim at stabilizing the structure of the 
peptide. Our biochemical data suggested that truncations beyond the sixth amino acid of 
the C-terminus may be increasing the flexibility of RJPXD33 and thereby decreasing 
binding affinity. Identification of sites which would allow for covalent linkage to 
minimize the flexibility of the peptide will be essential to the development of more potent 
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analogues. This may be accomplished through covalent linkage of the solvent exposed 
residues, or potentially through a hydrophobic linker between the threonine and leucine 
side chains. However, the latter may be difficult to achieve while maintaining the stereo-
specificity required for the peptide to bind.  
 A fundamental understanding of how the small molecule inhibitors are binding to 
LpxD will be essential for a guided structure-activity relationship (SAR) campaign for 
increasing potency and bioavailability. A structural approach can be pursued; however an 
alternative approach would be the design of small molecule probes with photo-affinity 
labels to provide a platform for mapping interactions to LpxD, much like the strategy 
utilized to map peptide binding. RJPXD33 is twelve amino acids long, thus providing a 
very large surface area for binding to LpxD. The small molecules identified may be 
binding in different areas of the groove between two monomeric subunits, and thus 
exploration of these small molecules may identify two unique binding modalities. Such 
unique binding modalities offers the potential for linking two small molecules together to 
increase potency, much like that of Fragment Based Drug Discovery (FBDD) (20,21). 
 While our studies have been limited to E. coli, it will be essential to perform 
broad spectrum studies on LpxD/A enzymes from other organisms. The photo-activatable 
peptides synthesized in chapter 4 could be used as a tool to quickly identify whether or 
not these peptides bind to LpxD/LpxA from other organisms. Rather than purifying each 
enzyme individually one could potentially perform such studies on whole-cell lysates. 
Binding affinity could then be ascertained on purified enzymes with the FITC-labeled 
probes. Optimization of such an assay in E. coli will be a prerequisite step before these 
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studies can be achieved. This can be further expanded to small molecule inhibitory 
probes, as described above. 
 In all, our work has provided a fundamental framework towards the future 
development of clinically utilized lipid A inhibitors. Our FP assays have already been 
recognized by the pharmaceutical industry as powerful tools for screening chemical 
libraries against LpxA (22). Future efforts aimed at the development of peptidomimetics 
and SAR around the small-molecule inhibitors identified in chapter 5 may culminate in 
the identification of dual-targeting, cell permeable inhibitor of LpxD/LpxA. Thus this 
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Peptide and Protein Purification Data 
 The following are protein purification gels for proteins used throughout our 
studies. 
 
Figure A.1. Various urified proteins. L. Ladder (numbers indicate mass in kDa), 1. LpxA (8 g) 2. N-His6 
LpxD (8 g) 3. ACP (~0.8 g) 4. Vibrio harveyi AasS (8 g) 5. MurA (8 g). Bands above 70 kDa in 





Figure A.2. LpxC protein purification. L. Ladder (numbers indicate mass in kDa) 1. Whole cell lysate 
before IMAC column. 2. Flow through of IMAC column. 3. Purified LpxC (~2.0 g). Other proteins 
visualized are purifications for LpxA and V. harveyi AasS. Bands above 80 kDa in order: 90, 100, 120, 





Figure A.3. ACP fractions following anion exchange. L. Ladder (numbers indicate mass in kDa) Fractions 
1 – 9 were pooled and utilized for acylation reactions. Bands above 70 kDa in order: 80, 90, 100, 120, 160, 
220 kDa. ACP is an 8.8 kDa protein that has been shown to run at approximately 19 – 20 kDa due to an 





Figure A.4. Native Urea Gel for ACP acylation reaction. Conditions used were 15% native polyacrylamide 
gel containing 2 M Urea. 1. Holo-ACP (5 mg) 2. R-3-hdroxyacyl-ACP (1 g) 3. R-3-hdroxyacyl-ACP (2.5 
























RJPXD31 QHFMVPDINDMQ-NH2 1473.6613 1473.6605 
RJPXD33 TNLYMLPKWDIP-NH2 1489.7871 1489.7864 
RJPXD34 SENNFMLPLLPL-NH2 1386.7449 1386.7467 
FITC-RJPXD33 FITC--TNLYMLPKWDIP-NH2 1949.8600 1949.8535 
FITC-P920 FITC--SSGWMLDPIAGKWSR-NH2 2149.9258 2149.9299 
FITC-RJPXD336 FITC--TNLYML-NH2 1213.4692 1213.4682 
RJPXD33C5 TNLYMLP-NH2 850.4491 850.4498 
RJPXD33C6 TNLYML-NH2 753.3964 753.3965 
RJPXD33C7 TNLYM-NH2 640.3123 640.3119 
RJPXD33C8 TNLY-NH2 509.2718 509.2712 
RJPXD33C9 TNL-NH2 346.2085 346.2082 
RJPXD33N1 NLYMLPKWDIP-NH2 1388.7395 1388.741 
RJPXD33N2 LYMLPKWDIP-NH2 1274.6965 1274.6964 
RJPXD33N3 YMLPKWDIP-NH2 1161.6125 1161.6118 
RJPXD33N4 MLPKWDIP-NH2 998.5491 998.5481 
RJPXD33N5 LPKWDIP-NH2 867.5087 867.5079 
RJPXD33N6 PKWDIP-NH2 754.4246 754.4246 
FITC-Photo1 FITC--TNXYMLPKWDIP-NH2 1961.8349 1961.8309 
FITC-Photo2 FITC--TNLZMLPKWDIP-NH2 1974.8665 1974.8640 
FITC-Photo3 FITC--TNLYMXPKWDIP-NH2 1961.8349 1961.8320 
FITC-Photo4 FITC--TNLYMLPKWDXP-NH2 1961.8349 1961.8298 
Biotin-Photo1* Biotin-C--TNXYMLPKWDIP-NH2 2103.9998 2104.0001 
Biotin-Photo3* Biotin-C--TNLYMXPKWDIP-NH2 2103.9998 2103.9959 
Biotin-Photo4* Biotin-C--TNLYMLPKWDXP-NH2 2103.9998 2103.9957 
 – -alanine. 
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